 
 
 
Any and all information presented in this document shall be treated  as confidential and shall remain the exclusive property of [COMPANY_011] (or any of its 
affiliated companies). The use of such confidential information must be restricted to the recipi[INVESTIGATOR_12950] d must not be 
disclosed, published or otherwise c ommunicated to any unauthorized persons, for any reason, in any form whatsoever without the prior written 
consent of [COMPANY_011] (or the concerned affiliated company); ‘affiliated company’ means any corporation, partnership or other ent ity which at the date 
of communication or afterwards (i) controls directly or indirectly [COMPANY_011], (ii) is directly or indirectly controlled by [CONTACT_13225], with ‘control’ meaning 
direct or indirect ownership of more than 50% of the capi[INVESTIGATOR_13040],  partnership or other entity  
According to Template: [COMPANY_011] OneDocument Version 4.0, dated 27 -JUL-2020  Page 1 
f 
AMENDED CLINICAL TRI AL PROTOCOL 02  
Protocol title:  A randomized, double -blind, placebo controlled, proof 
of concept study assessing the efficacy and safety of 
the RIPK1 -inhibitor SAR443122 in patients with 
moderate to severe subacute or discoid/chronic 
cutaneous lupus erythematosus  
Protocol number:  ACT16404  
Amendment number:  02 
Compound number 
(INN/Trademark) : SAR443122  
Brief title:  Proof of concept study of SAR443122 in patients with 
cutaneous lupus erythematosus  
CLEan  
Study phase:  Phase 2  
Sponsor name:  [CONTACT_13225] -Aventis Recherche & Développement  
Legal registered 
address:   1 avenue Pi[INVESTIGATOR_12954]  
[ZIP_CODE] Chilly Mazarin Cedex  
[LOCATION_009]  
Manufacturer:  Same as Sponsor  
Monitoring team’s 
representative name [CONTACT_13255] [CONTACT_225339](s):  
IND: [ADDRESS_270905]:  [ADDRESS_270906]:  [STUDY_ID_REMOVED]  
WHO:  U1111 -1246 -6784  
EUDAMED : Not applicable  
Other : Not applicable  
 
Date:  22-Nov-2022  Total number of pages:  126 
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 2 PROTOCOL AMENDMENT S UMMARY OF CHANGES   
DOCUMENT HISTORY  
 
Document  Country/countries 
impacted by 
[CONTACT_13097], version  
Amended Clinical Trial protocol 02  All 22-Nov-2022 , version 1 (electronic 2.0) 
Amended Clinical Trial protocol 01  All 10-Dec-2021, version 1 (electronic 1.0)  
Original Protocol   11-Dec-2020, version 1 (electronic 2.0)  
Amended Clinical Trial protocol 02  (22 November  2022 ) 
This amended clinical trial protocol 02 (amendment 02) is considered to be not substantial based 
on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and 
the Council of the European Union. Because it does not significantly impact the safety or 
physical/mental integrity of participant s, nor the scientific value of the study.  
OVERALL RATIONALE FOR THE AMENDMENT  
The main purpose of this amendment is to include an interim analysis. The sponsor will make use 
of this interim analysis  to facilitate internal operational decision on the compou nd development. 
For the details of the interim analysis , see Section  9.4. 
Protocol amendment summary of changes ta ble 
Section # and Name  [CONTACT_9353] 9.3 Statistical 
analyses  Added:  
The SAP will be developed and finalized prior to 
database lock or any interim analysis.  To provide more precision.  
Section 9.4 Interim analysis  Added:  
An interim analysis is planned for this study. The 
sponsor will make use of this interim analysis  to 
facilitate internal operational decision on the 
compound development. The interim analysis will 
be performed when around 75% of the patients 
have completed  study treatment or discontinued 
the study. The interim analysis will not lead to 
changes in the conduct of the protocol other than 
stoppi[INVESTIGATOR_225299], indicating a lack of equipoise for continued 
recruitment of patients. The details including the 
pre-specified rules for stoppi[INVESTIGATOR_225300].  An interim analysis is planned to facilitate 
internal operational decision on the 
compound development.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 3 Section # and Name  [CONTACT_225419] -A at 
Week  12 and other selected secondary efficacy 
endpoints, as well as the safety endpoints as 
needed. The PK and PD relationship could also 
be explored.  
The interim analysis will be performed by 
a separate statistical t eam, independent of the 
study team. The PK/PD analysis will be 
performed by a sponsor internal modeling and 
simulation team, also independent of the study 
team. Only those necessary for conducting the 
interim analysis and those responsible for internal 
project planning/overall portfolio planning needs 
(eg, to aid in the planning of future studies) will 
have the access to the interim analyses results 
before study completion.  A list of these 
individuals will be maintained.  
All sponsor internal personnel with  access to 
unblinding information will be asked to sign 
a study confidentiality agreement before having 
access to unblinding information. Study team and 
investigational sites will not have access to 
interim study results, and continue to be blinded 
to indi vidual randomization codes until study 
completion and database lock  
Section 10.1.6 Dissemination 
of clinical study data ; 
Study  participants  Replaced “clinicalstudydatarequest.com” to 
“vivli.org”  To correct the website address for 
dissemination of clinical study data of 
study participants.  
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: [ADDRESS_270907] OF FIGURES  ................................ ................................ ................................ ................................ ..........  9 
1 PROTOCOL SUMMARY  ................................ ................................ ................................ ...............  10 
1.1 SYNOPSIS  ................................ ................................ ................................ ................................ ..... 10 
1.2 SCHEMA  ................................ ................................ ................................ ................................ ........  15 
1.3 SCHEDULE OF ACTIVITI ES (SOA)  ................................ ................................ ..............................  16 
2 INTRODUCTION  ................................ ................................ ................................ ............................  21 
2.1 STUDY RATIONALE ................................ ................................ ................................ ......................  24 
2.2 BACKGROUND  ................................ ................................ ................................ .............................  24 
2.3 BENEFIT/RISK ASSESSM ENT ................................ ................................ ................................ ..... 25 
2.3.1  Risk assessment  ................................ ................................ ................................ ............................  25 
2.3.2  Benefit assessment  ................................ ................................ ................................ ........................  27 
2.3.3  Overall benefit: risk conclusion  ................................ ................................ ................................ ...... 27 
3 OBJECTIVES AND ENDPO INTS  ................................ ................................ ................................ . 29 
3.1 APPROPRIATENESS OF M EASUREMENTS  ................................ ................................ ..............  30 
4 STUDY DESIGN  ................................ ................................ ................................ ............................  33 
4.1 OVERALL DE SIGN  ................................ ................................ ................................ ........................  33 
4.2 SCIENTIFIC RATIONALE  FOR STUDY DESIGN  ................................ ................................ .........  34 
4.2.1  Participant input into design  ................................ ................................ ................................ ...........  35 
4.3 JUSTIFICATION FOR DO SE ................................ ................................ ................................ ........  35 
4.4 END OF STUDY DEFINIT ION ................................ ................................ ................................ ....... 35 
5 STUDY POPULATION  ................................ ................................ ................................ ..................  36 
5.1 INCLUSION CRITERIA  ................................ ................................ ................................ ..................  36 
5.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ...............  38 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 5 5.3 LIFESTYLE CONSIDERAT IONS  ................................ ................................ ................................ ... 41 
5.3.1  Meals and dietary restrictions  ................................ ................................ ................................ ........  41 
5.3.2  Caffeine, alcohol, and tobacco  ................................ ................................ ................................ ....... 41 
5.3.3  Activity  ................................ ................................ ................................ ................................ ............  41 
5.4 SCREEN FAILURES ................................ ................................ ................................ ......................  41 
5.5 CRITERIA FOR TEMPORA RILY DELAYING 
(ENROLLMENT/RANDOMIZ ATION/ADMINISTRATION  OF STUDY INTERVENTI ON) .............  42 
6 STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY  ................................ ...................  43 
6.1 STUDY INTERVENTION(S ) ADMINISTERED  ................................ ................................ ..............  [ADDRESS_270908]  ................................ ................................ ...........................  45 
6.1.3  Devices  ................................ ................................ ................................ ................................ ..........  45 
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY................................ .......................  45 
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING  ................................ ....... 46 
6.4 STUDY INTERVENTION C OMPLIANCE  ................................ ................................ ......................  47 
6.5 DOSE MODIFICATION  ................................ ................................ ................................ ..................  47 
6.5.1  Retreatment criteria ................................ ................................ ................................ ........................  47 
6.6 CONTINUED ACCESS TO INTERVENTION AFTER T HE END OF THE STUDY .......................  47 
6.7 TREATMENT OF OVERDOS E ................................ ................................ ................................ ...... 48 
6.8 CONCOMITANT THERAPY  ................................ ................................ ................................ ..........  48 
6.8.1 Prohibited medications  ................................ ................................ ................................ ...................  48 
6.8.2  Topi[INVESTIGATOR_11930]  ................................ ................................ ................................ ...................  49 
6.8.3  Systemic corticosteroids  ................................ ................................ ................................ ................  49 
6.8.4  Intra-articular, intralesional, intranasal, and inhaled corticosteroids  ................................ ..............  49 
6.8.5  Chloroquine and hydroxychloroquine  ................................ ................................ ............................  49 
6.8.6  Nonsteroidal anti -inflammatory drugs, topi[INVESTIGATOR_12866], acetaminophen and other 
analgesic  ................................ ................................ ................................ ................................ ........  49 
6.8.7  Drug interaction  ................................ ................................ ................................ ..............................  50 
6.8.8  Rescue medications  ................................ ................................ ................................ .......................  50 
7 DISCONTINUATION OF STU DY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITH DRAWAL  ................................ ................................ ...........................  51 
7.1 DISCONTINUATION OF S TUDY INTERVENTION  ................................ ................................ ..... 51 
7.1.1  Perm anent  discontinuation  ................................ ................................ ................................ ............  51 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 6 [IP_ADDRESS]  Handling of participants after permanent intervention discontinuation  ................................ ..........  52 
7.1.2  Liver chemistry stoppi[INVESTIGATOR_3418]  ................................ ................................ ................................ .... 52 
7.1.3  QTc stoppi[INVESTIGATOR_3418]  ................................ ................................ ................................ ......................  52 
7.1.4  Temporary discontinuation  ................................ ................................ ................................ .............  52 
7.1.5  Rechallenge  ................................ ................................ ................................ ................................ ... 52 
[IP_ADDRESS]  Study intervention restart or rechallenge after liver stoppi[INVESTIGATOR_31735]  ................................ ...... 53 
7.2 PARTICIPANT DISCONTINUATION/WITH DRAWAL FROM THE STUD Y ................................ .. [ADDRESS_270909] TO FOLLOW UP  ................................ ................................ ................................ .................  54 
8 STUDY ASSESSMENTS AN D PROCEDURES  ................................ ................................ ...........  55 
8.1 EFFICACY ASSESSMENTS   ................................ ................................ ................................ ........  55 
8.1.1 Cutaneous lupus Erythematosus Disease Area and Severity Index (CLASI)  ...............................  55 
8.1.2  Physician Global Assessment of disease activity (PhysGA - disease activity) for cutaneous 
lupus erythematosus  ................................ ................................ ................................ ......................  56 
8.1.3  Physician Global Assessment of Change in cutaneous  lupus erythematosus activity 
(PGAC)  ................................ ................................ ................................ ................................ ...........  56 
8.1.4  Patient -reported Numerical Rating Scale (NRS)  ................................ ................................ ...........  57 
8.1.5  Investigator’s Global Assessment for Cutaneous Lupus Erythematosus (IGA -CLE)  ....................  [ADDRESS_270910] Profile 14 -item version (OHIP -14) ................................ ................................ ... 58 
8.1.7  SKINDEX -29+3  ................................ ................................ ................................ ..............................  58 
8.1.8  Patient Global Impression of disease severity (PGIS) and Patient Global Impression of 
Change (PGIC) in cutaneous lupus erythematosus  ................................ ................................ ...... 59 
8.1.9  28-Joint assessment  ................................ ................................ ................................ ......................  59 
8.1.10  Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic Lupus 
Erythematosus Disease Activity Index (SELENA -SLEDAI)  ................................ ...........................  59 
8.1.11  Genital Erosive Lichen Planus (GELP) score  ................................ ................................ ................  59 
8.1.12  Photography of Index Lesion  ................................ ................................ ................................ .........  60 
8.2 SAFETY ASSESSMENTS  ................................ ................................ ................................ ............  60 
8.2.1  Physical examinations  ................................ ................................ ................................ ...................  60 
8.2.2  Vital signs  ................................ ................................ ................................ ................................ ....... 61 
8.2.3  Electrocardiograms  ................................ ................................ ................................ ........................  61 
8.2.4  Clinical safety laboratory assessments  ................................ ................................ ..........................  61 
8.2.5  Suicidal ideation and behavior risk monitoring  ................................ ................................ ..............  62 
8.3 ADVERSE EVENTS (AES) , SERIOUS ADVERSE EV ENTS (SAES) AND OTHER 
SAFETY REPORTING  ................................ ................................ ................................ ...................  62 
8.3.1  Time period and frequency for collecting AE and SAE information  ................................ ...............  62 
8.3.2  Method of detecting AEs and SAEs  ................................ ................................ ...............................  63 
8.3.3  Follow -up of AEs and SAEs  ................................ ................................ ................................ ...........  63 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 7 8.3.4  Regulatory reporting requirements for SAEs  ................................ ................................ .................  63 
8.3.5  Pregnancy  ................................ ................................ ................................ ................................ ...... 64 
8.3.6  Cardio vascular and death events  ................................ ................................ ................................ .. 64 
8.3.7  Disease -related events and/or disease -related outcomes not qualifying as AEs or SAEs  ...........  [ADDRESS_270911] complaints  ................................ ................................ ..................  65 
[IP_ADDRESS]  Medical device deficiencies  ................................ ................................ ................................ ...........  65 
8.4 PHARMACOKINETICS  ................................ ................................ ................................ ..................  65 
8.4.1  Pharmacokinetics handling procedure  ................................ ................................ ...........................  66 
8.4.2  Bioanalytical method  ................................ ................................ ................................ ......................  66 
8.4.3  Pharmacokinetic parameters  ................................ ................................ ................................ .........  66 
8.5 GENETICS  ................................ ................................ ................................ ................................ ..... 66 
8.6 BIOMARKERS  ................................ ................................ ................................ ...............................  67 
8.7 IMMUNOGENICITY ASSES SMENTS  ................................ ................................ ...........................  68 
8.8 HEALTH ECONOMICS  ................................ ................................ ................................ ..................  68 
8.9 USE OF BIOLOGICAL SA MPLES AND DATA FOR F UTURE RESEARCH  ................................  68 
9 STATISTICAL CONSIDER ATIONS  ................................ ................................ ..............................  70 
9.1 SAMPLE SIZE DETERMIN ATION  ................................ ................................ ................................ . 70 
9.2 POPULATIONS FOR ANAL YSES  ................................ ................................ ................................ . 70 
9.3 STATISTICAL ANALYSES  ................................ ................................ ................................ ............  70 
9.3.1  General considerations  ................................ ................................ ................................ ..................  71 
9.3.2  Primary endpoint(s)  ................................ ................................ ................................ ........................  71 
9.3.3  Secondary endpoint(s)  ................................ ................................ ................................ ...................  72 
9.3.4  Exploratory endpoint(s)  ................................ ................................ ................................ ..................  72 
9.3.5  Analyses of safety data  ................................ ................................ ................................ ..................  72 
[IP_ADDRESS]  Adverse events  ................................ ................................ ................................ ..............................  73 
[IP_ADDRESS]  Vital signs  ................................ ................................ ................................ ................................ ....... 74 
[IP_ADDRESS]  Clinical safety laboratory  ................................ ................................ ................................ ................  74 
[IP_ADDRESS]  Electrocardiogram  ................................ ................................ ................................ ..........................  75 
9.3.6  Analyses of pharmacokinetic data  ................................ ................................ ................................ . 75 
[IP_ADDRESS]  Pharmacokinetic parameters  ................................ ................................ ................................ .........  75 
[IP_ADDRESS]  Pharmacokinetic/Pharmacodynamic analysis  ................................ ................................ ...............  75 
9.4 INTERIM ANALYSES  ................................ ................................ ................................ ...................  75 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS  ........................  76 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 8 10.1  APPENDIX 1: REGULATO RY, ETHICAL, AND STU DY OVERSIGHT CONSIDE RATIONS  ....... 76 
10.1.1  Regulatory and ethical considerations  ................................ ................................ ...........................  76 
10.1.2  Financial disclosure ................................ ................................ ................................ ........................  77 
10.1.3  Informed consent process  ................................ ................................ ................................ ..............  77 
10.1.4  Data protection  ................................ ................................ ................................ ...............................  78 
10.1.5  Committee structure  ................................ ................................ ................................ .......................  80 
[IP_ADDRESS]  Internal Safety Review Committee  ................................ ................................ ................................ . 80 
10.1.6  Dissemination of clinical study data  ................................ ................................ ...............................  81 
10.1.7  Data quality assurance  ................................ ................................ ................................ ..................  81 
10.1.8  Source documents  ................................ ................................ ................................ .........................  82 
10.1.9 Study and site start and closure  ................................ ................................ ................................ ..... 82 
10.1.10  Publication policy  ................................ ................................ ................................ ...........................  83 
10.2  APPENDIX 2: CLINICAL  LABORATORY TESTS  ................................ ................................ .........  83 
10.3  APPENDIX 3: AES AND SAES: DEFINITIONS AN D PROCEDURES FOR REC ORDING, 
EVALUATING, FOLLOW -UP, AND REPORTING  ................................ ................................ .........  85 
10.3.1  Definition of AE  ................................ ................................ ................................ ..............................  85 
10.3.2  Definition of  SAE ................................ ................................ ................................ ............................  87 
10.3.3  Recording and follow -up of AE and/or SAE  ................................ ................................ ...................  88 
10.3.4  Reporting of SAEs ................................ ................................ ................................ ..........................  90 
10.4  APPENDIX 4: CONTRACE PTIVE AND BARRIER GUIDANCE  ................................ ...................  91 
10.4.1  Definitions  ................................ ................................ ................................ ................................ ...... 91 
10.4.2  Contraception guidance  ................................ ................................ ................................ .................  92 
10.5  APPENDIX 5: GENETICS  ................................ ................................ ................................ .............  94 
10.6  APPENDIX 6: LIVER AN D OTHER SAFETY: SUGG ESTED ACTIONS AND FO LLOW -UP 
ASSESSMENTS AND STUD Y INTERVENTION RECHA LLENGE GUIDELINES  .......................  95 
10.7  APPENDIX 7: AES, ADE S, SAES, SADES, [LOCATION_003]D ES AND DEVICE DEFICI ENCIES: 
DEFINITIONS AND PROC EDURES FOR RECORDING , EVALUATING, FOLLOW -UP, 
AND REPORTING IN  MEDICAL DEVICE STUD IES ................................ ................................ .... 99 
10.8  APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENT S ................................ ..............................  99 
10.9  APPENDIX 9: CONTINGE NCY MEASURES FOR A R EGIONAL OR NATIONAL 
EMERGENCY THAT IS DE CLARED BY A GOVERNME NTAL AGENCY  ................................ . 100 
10.10  APPENDIX 10: ADDITIO NAL APPENDICES  ................................ ................................ ..............  [ADDRESS_270912] of topi[INVESTIGATOR_11930]  ................................ ................................ ................................ ........  102 
10.10.2  Sample of Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)  ...........  104 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 9 10.10.3  Sample of Physician Global Assessment of disease activity (PhysGA - disease activity) and 
Physi cian Global Assessment of changes in cutaneous lupus erythematosus activity 
(PGAC)  ................................ ................................ ................................ ................................ .........  105 
10.10.4  Sample of Patient -Reported Peak Pr uritus Numerical Rating Scale (itch -NRS) and Peak 
Pain Numerical Rating Scale (Pain -NRS)  ................................ ................................ ....................  [ADDRESS_270913]  Profile (OHIP -14) ................................ ................................ .........  107 
10.10.6  Sample of SKINDEX -29+3  ................................ ................................ ................................ ...........  111 
10.10.7  Sample of Patient Global Impression of Change (PGIC) and Severity (PGIS) in cutaneous 
lupus erythematosus  ................................ ................................ ................................ ....................  114 
10.10.8  Sample of Investigator’s Global Assessment for Cutaneous Lupus Erythematosus Activity 
(IGA-CLE)  ................................ ................................ ................................ ................................ .... 115 
10.11  APPENDIX 11: ABBREVI ATIONS  ................................ ................................ ...............................  117 
10.12  APPENDIX 12: PROTOCO L AMENDMENT HISTORY  ................................ ..............................  118 
10.12.1  Amended protocol 01 (10 DEC 2021)  ................................ ................................ ..........................  [ADDRESS_270914] OF FIGURES   
Figure  1 - Graphical study design  ................................ ................................ ................................ .................  15 
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 10 1 PROTOCOL SUMMARY   
1.1 SYNOPSIS   
Protocol title:   
A randomized, double -blind, placebo controlled, proof of concept study assessing 
the efficacy and safety of the RIPK1 -inhibitor SAR443122 in patients with moderate 
to severe subacute or discoid/chronic cutaneous lupus erythematosus  
Brief title:   
Proof of concept study of SAR443122 in patients with cutaneous lupus erythematosus  
Rationale:  
SAR443122 is a novel, potent and selective Receptor -Interacting serine -threonine Protein Kinase1 
(RIPK1 ) inhibitor. The RIP Kinase function involved in pro -inflammatory signaling via 
phosphorylated RIPK1/3 ( pRIPK1/3)  and phosphorylated mixed lineage kinase domain -like 
protein  (pMLKL ) leading to membrane pore formation, cell death and the release of danger -
associated molecular patterns (DAMPs ) is inhibited by [CONTACT_13108]443122.  
In interface dermatitis (ID ), a group of skin autoimmune diseases, which is characterized by 
[CONTACT_225340] e epi[INVESTIGATOR_225301]. A dysregulated immune response to keratinocyte damage caused by 
[CONTACT_225341] (UV ) light and potentially other stimuli are considered drivers of I D which includes 
most cutaneous lupus erythematosus (CLE ) forms.  
All subtypes of cutaneous lupus can be triggered and worsened by [CONTACT_225342]. The manifestations of 
lupus on skin most often involv es the scalp, face, ears, and/or other sun -exposed areas. Some 
patients may present oral and/or genital lesions. Sometimes patients may feel pain or itch. Skin 
lesion can lead to permanent damage such as depi[INVESTIGATOR_371], scaring and even hair loss when the 
scalp is involved. CLE skin manifestations in sun exposed area like scalp and face can be 
disfiguring and are a significant cause of morbidity.  
In Europe and the [LOCATION_003], the incidence of isolated CLE is ~4 cases per 100 000 persons per year. 
Skin involvement  occurs in 70% -80% of all patients with systemic lupus erythematosus (SLE ) 
during the course of their disease and patients with CLE can progress to SLE with internal organ 
systems involvement.  
Existing options to treat subacute and chronic lupus are limited and the standards of care consist 
of repurposed drugs with limited evidence supporting their efficacy and with considerable safety 
issues. There is a high unmet need for therapi[INVESTIGATOR_225302].  
SAR443122 is proposed to target the chronic inflammation in participants with CLE which 
manifests as interface dermatitis, namely chr onic cutaneous lupus erythematosus (CCLE )/discoid 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 11 lupus erythematosus (DLE ) or subacute cutaneous lupus erythematosus (SCLE ). RIPK1 inhibition 
may prevent the damage inflicted on keratinocytes and reduce the pro -inflammatory response to 
this damage, thereby [CONTACT_225343] s. 
The available nonclinical and clinical data from the SAR443122 development program in healthy 
volunteers demonstrated that SAR443122 is well tolerated with a good safety profile which 
allows for high exposure and tissue penetration in the skin with the opportunity to achieve high 
exposure in target cells.  
Objectives and endpoints   
 
 
 
 
 
Objectives  Endpoints  
Primary  
• Assess the efficacy of SAR443122 in CLE  • Percent change from baseline in Cutaneous 
Erythematosus Disease Area and Severity Index 
activity (CLASI -A) sub -score at Week 12  
Secondary  
• Assess the effect of SAR443122 on the physician’s 
global assessment of disease activity 
(PhysGA - disease activity)  • Proportion of patients with PhysGA - disease 
activity of 0 or 1 (disease free or alm ost disease 
free) at Week 12  
• Assess the effect of SAR443122 on CLE induced 
itch and overall pain  • Change from baseline in patients reported daily 
worst itch using Peak Pruritus Numerical Rating 
Scale (itch -NRS) at Week 12  
• Change from baseline in patients reported daily 
worst pain using Peak Pain Numerical Rating 
Scale (Pain -NRS) at Week 12  
• Assess the effect of SAR443122 on the proportion 
of disease activity responders compared to 
placebo  • Proportion of CLASI -A50 and CLASI -A75 
responders at Week 12  
• Assess the effect of SAR443122 on the CLASI 
components’ score  • Change from baseline in CLASI components' score 
over time  
• Assess the effect of SAR443122 on the 
Investigator’s global assessment for CLE (IGA -
CLE)  • Proportion of patients with I GA-CLE score of 0 or 1 
(clear or almost clear) at Week 12  
• Assess oral cavities for patients with oral lesions  • Change from baseline to Week [ADDRESS_270915] Profile (OHIP -14) for patients with 
oral lesions at baseline  
• Assess the disease specific quality of life (QoL)  • Change from baseline in SKINDEX -29+3 total 
score at Week 12  
• Assess the safety and tolerability of SAR443122 in 
patients with CLE  • Total number and percent of treatment -emergent 
adverse events (TEAEs), serious adverse events 
(SAEs), adverse events of special interest (AESIs)  
• Percent of potentially clinically significant 
abnormalities (PCSAs) in laboratory tests, 
electrocardiogram (ECG) or vital signs through end 
of study (EOS)  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 12 Objectives  Endpoints  
• Assess the pharmacokinetics (PK) exposure of 
SAR443122 in patients with CLE  • SAR443122 plasma concentration  
• Pharmacokinetic parameters (maximum 
concentration [C max], time to C max [tmax], area under 
the curve over the dosing interval [AUC 0-tau], and 
elimination half -life [t 1/2z]) 
 
 
 
 
Overall design:  
This is a multinational, multi -center, randomized, double -blind parallel group 12 -week treatment 
study to evaluate efficacy and safety of the RIPK1 -inhibitor SAR443122 dosed at 300 mg 
twice  a day (BID ) compared to matching placebo in patients with moderate to severe SCLE or 
DLE.  
The target population for the study is patients with histologically confirmed SCLE or DLE. 
Patients with acute CLE, drug induced l upus, certain chronic CLE subtypes (eg, LE timidus, lupus 
profundus, chilblain LE, LE -lichen planus overlap) or lupus like syndrome are excluded. Patients 
with SLE may be included provided they do not have significant involvement of the central 
nervous sys tem (CNS ), lung or kidney such as lupus nephritis.  
The study will be blinded to investigators, patients and [COMPANY_011] as well as [COMPANY_011] contracted staff.  
Participants will be randomized in a ratio of 1 :1 to either SAR443122 or placebo arm. The 
randomization will be stratified by [CONTACT_225344] (DLE or SCLE), baseline use of chloroquine 
or hydroxychloroquine (yes/no) and by [CONTACT_11338]. Up to [ADDRESS_270916] (IMP ), expecting a total of approximately 
[ADDRESS_270917] a screening  period of up to 4 weeks to assess eligibility, a treatment 
period of 12 weeks beginning from the day of randomization (Baseline, Day 1) and a [ADDRESS_270918] 
treatment follow -up period.  
At screening, participants without a documented histological diagnosis of  CLE within 1 year prior 
to Screening will need a biopsy during Screening period with a histological confirmation of CLE 
diagnosis before randomization. For participants with a documented histological diagnosis of CLE 
within 1 year prior to Screening, a bi opsy will be performed at Baseline, while the eligibility 
related to CLE diagnosis will be based upon the historical documented result.  
During the 12 -week treatment period, participants will be assessed by [CONTACT_225345] 4 weeks 
and undergo clinical l aboratory examinations for all protocol required assessments. Patient -reported 
disease symptoms (itch and pain) will be assessed on a daily basis within two  weeks and at least 
4 days prior to baseline and during the treatment period. Details are in Section  1.3. 
The primary objective of the study is to assess disease activity compared with placebo at Week 12 
as measured by [CONTACT_225346] ( 2, 3) 
activity (CLASI -A ) sub -score. The secondary endpoints include  Investigator’s Glo bal 
Assessment of CLE (IGA -CLE ), Physician’s Global Assessment of disease activity (PhysGA - 
disease activity ) at Week 12, assessments of CLE -induced itch and pain evaluated separately daily 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 13 by a patient reported numerical rating scale, the comparison of CLASI -A50, CLASI -A75 
responder rate, and change from baseline of CLASI indivi dual components score ( 4). A quality of 
life instrument SKINDEX -29+3 will be used for quality of life assessment ( 5). 
During the study, rescue medication may be used in cases where there is worsening of signs or 
symptoms of CLE per Investigator’s assessment. If feasible, rescue medi cation should not be used 
for at least [ADDRESS_270919] administration of study intervention. Details are provided 
in Section  6.8.8 . 
An internal safety review committee (ISRC ) will be established to oversee the welfare of the 
participants as well as the saf ety, scientific integrity of the trial. All members in the committee are 
independent of the study operational team members. Details regarding the composition, mandate 
and function of the internal safety review committee will be provided in the respective I SRC 
charter.  
Brief summary :  
This is a parallel , treatment , Phase 2, participants, outcome assessors and Investigator masked , 
2-arm study to assess the efficacy and safety of SAR443122 compared to placebo in male and 
female participants aged 18  to 80 years with moderate to severe SCLE or DLE.  
Number of participants:  
A maximum of 88 participants will be randomized to study intervention with the goal of 
approximately 80 participants to complete the study and that are evaluable for the analysis  of the 
primary endpoint.  
Intervention groups and duration : 
This study will include two treatment groups: SAR443122 and Placebo.  
Total study duration per participant will be up 20 weeks including:  
• A screening period of up to 4 weeks  
• A treatment perio d of 12 weeks  
• A post treatment follow -up period of 4 weeks  
Study intervention(s)  
Investigational medicinal product(s)  
• Formulation: capsules of either SAR443122 100 mg or matching placebo  
• Route(s) of administration: Oral route  
• Dose regimen: 300 mg BID fo r 12 weeks  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404   22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 14 Non-investigational medicinal products(s)  
• Rescue treatment may be used per investigators’ judgement during the study. Topi[INVESTIGATOR_225303]/or topi[INVESTIGATOR_125039]/or one short course of oral 
corticosteroids of up to 10 da ys are allowed. Initiation of any new topi[INVESTIGATOR_12870]/or topi[INVESTIGATOR_125039]/or increase potency for treating CLE will be 
considered a rescue treatment. Only one  course of oral corticosteroids of up to ten days 
duration is permit ted. If other systemic rescue medications such as immunosuppressants 
(except initiation or increase the dose of chloroquine or hydroxychloroquine) are required, 
the patient should be permanently discontinued from the study drug but they should be 
encourage d to stay in the study until the end of the study.  
Devices: Not applicable  
Posttrial access to study medication: Not planned  
Statistical considerations:  
• The sample size was derived to address the primary endpoint (percent change from 
Baseline to Week 12 in the CLASI -A sub-score) by [CONTACT_225347].  
Data Monitoring/Other committee:  Yes (ISRC - described previously)  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 15 1.2 SCHEMA    
Figure  1 - Graphical study design   
  
4 weeks  
End of study 
(EOS)  
Screening  
Up to 
28 days 
Double -blind treatment period  (12 weeks)  
4 weeks  
follow -up  
R
Screening D -28 
 D1/WK0  
Randomization stratified by 
[CONTACT_225348], baseline use 
of chloroquine or 
hydroxychloroquine 
(yes/no), and region  
Start of double -blind 
treatment  
D85/WK 12  
End of treatment (EOT ) 
Primary Endpoint  
(%-Change in CLASI -A) 
N= 44   Placebo BID  
Patients with histologically 
proven subacute or 
discoid/chronic CLE  
•CLASI -A >=10  
•No major organ 
manifestations in 
patients with SLE  
N= 44   SAR443122, 300 mg BID    
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 16  
1.3 SCHEDULE OF ACTIVITI ES (SOA)    
 
 Screening  
(4 weeks)  Treatment phase  Follow -up 
Visit  V1 V2  
Baseline  V3a V4 V5 (EOT)   V6 (EOS )  
Day D-28 to D -1  
(Maximum 28 days)  D1  D29  
(±4) D57 
(±4) D 85   D 113 (+4)   
Week   Wk 0  Wk 4  Wk 8  Wk 12  Wk 16  
Informed consent  X      
Inclusion/exclusion criteria  X X     
Patient demographics  X      
Medical/surgical history (includes substance usageb) and Family 
history of premature CV disease  X      
Prior medications history  X      
Concomitant medication (including sun protectionc)  
X X X X X 
12-lead electrocardiogram (ECG)   X   
 X Xd 
Physical examination including vital signse X X X X X X 
Serology: Hepatitis B  & C, and HIVf X      
Antiphospholipid antibodiesg  X     
Antihistone autoantibodies  X      
Tuberculosis  (TB) testingh X      
COVID -19 testingh  X      
Height  X      
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 17  Screening  
(4 weeks)  Treatment phase  Follow -up 
Visit  V1 V2  
Baseline  V3a V4 V5 (EOT)   V6 (EOS )  
Day D-28 to D -1  
(Maximum 28 days)  D1  D29  
(±4) D57 
(±4) D 85   D 113 (+4)   
Week   Wk [ADDRESS_270920] (IMP)  
IMP daily intake (BID)i  X----------------------------------------------------------------- I  
IMP dispense   X X X   
IMP compliance (Patient diary)   X X X X  
Safety  
Adverse event/SAE recording  X----------------------------------------------------------------------------------------------------------------------------- ----------------------- > 
Tuberculosis risk assessment   
X   X  
Hematology, Chemistry  X X X X X Xd 
Fasting lipi[INVESTIGATOR_805], glycosylated hemoglobin (HbA1c)  X  
   
 
Urinalysisj X X X X X  
Serum pregnancy test (woman of childbearing potential 
[WOCBP ] only)  X      
Urine pregnancy test (WOCBP only)   X X X X X 
Efficacy assessment  
CLASIk X X X X X X 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 18  Screening  
(4 weeks)  Treatment phase  Follow -up 
Visit  V1 V2  
Baseline  V3a V4 V5 (EOT)   V6 (EOS )  
Day D-28 to D -1  
(Maximum 28 days)  D1  D29  
(±4) D57 
(±4) D 85   D 113 (+4)   
Week   Wk 0  Wk 4  Wk 8  Wk 12  Wk 16  
IGA-CLE X X X X X X 
PhysGA -disease activity  X X X X X X 
28-Joint assessment   X X X X X 
SELENA -SLEDAIl  X   X  
GELPn  X   X  
OHIP -14m  X   X  
SKINDEX 29+3   X   X  
Itch-NRS/Pain -NRSo <------------------------------------------------- daily--------------------------------------------------------------- >  
Physician Global Assessment of Change in disease activity    
  X  
Patient Global Impression of change in disease      X  
Patient Global Impression of disease severity   X   X  
Skin examination with photography of index lesion(s)   X   Xu  
PK and exploratory Biomarkers  
PK (plasma)p  X  
X Xu  
pS166 -RIPK1 (PBMC)q  X  
  X X 
Cytokine panel (Plasma) r  X X X X X 
Chemokine Panel (Plasma)r  X X X X X 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 19  Screening  
(4 weeks)  Treatment phase  Follow -up 
Visit  V1 V2  
Baseline  V3a V4 V5 (EOT)   V6 (EOS )  
Day D-28 to D -1  
(Maximum 28 days)  D1  D29  
(±4) D57 
(±4) D 85   D 113 (+4)   
Week   Wk 0  Wk 4  Wk 8  Wk 12  Wk 16  
RNA sequencing (Whole Blood) (optional)   X   X  
Marker for systemic lupus ( anti-dsDNA -ab, C3, C4)s  X   X  
Markers for systemic lupus (antinuclear antibody [ANA ], 
anti-Smith -ab)s  X     
Skin biopsy for histology, and RNA sequencingt Xt Xt   Xu  
DNA sample (optional)   X     
Abbreviation: ANA = antinuclear antibody; BID = twice a day; CLASI = Cutaneous Erythematosus Disease Area and Severity Index;  CV= cardiovascular; ECG = electrocardiogram; GELP= Genital Erosive Lichen 
Planus ; HIV = human immunodeficiency virus; IGA -CLE = Investigator's Global Assessment of CLE; IMP = investigational medicinal product; NRS = Nu merical Rating Scale ; OHIP = Oral Health Impact Profile ; 
PBMC  = peripheral blood mononuclear cell ; PD = pharmacodynamics ; PK = pharmacokinetics ; SAE = serious adverse event; SELENA -SEDAI = Safety of Estrogens in Lupus Erythem atosus National Assessment -
SLE Disease Activity Index ; SLE = systemic lupus erythematosus; TB = tuberculosis; WOCBP = woman of childbearing potential  
a In case of urgent COVID -[ADDRESS_270921] confinement of population, visit can be or ganized and done by [CONTACT_225349]’s judgement. Appropriate measure should be put in place for laboratory 
procedures (eg, home nursing).  
b Substances: drugs, alcohol, tobacco, and caffeine.  
c Sun protection information includes the level of daily sun exposure  and means for UV protection.  
d Only if there are abnormal findings at Wk12 requiring follow -up. 
e Full physical examination at screening only, including skin, nasal cavities, eyes, ears, respi[INVESTIGATOR_696], cardiovascular, gastroi ntestinal, neurological, lymphatic, and  musculoskeletal systems. A brief physical 
examination will be performed at remaining on -site visits and include, at a minimum, assessments of the skin, lungs, cardiovascular system, lymphatic system (include but n ot limited to cervical, axillary, inguinal  
and clavicular lymph nodes) and abdomen (liver and spleen).  
f HBV and HCV serologies include: hepatitis B surface antigen (HBs -Ag), hepatitis B surface antibody (HBs -Ab), total hepatitis B core antibody (HBc -Ab), and hepatitis C antibody (HCV -Ab). In case of HBc -Ab 
positive and HBs -Ag negative, to assess patient’s eligibility, HBV DNA will be performed locally as per Investigator’s judgement.  
g Antiphospholipid antibodies to be performed in patients with SLE.  
h TB testing method will follow local guidelines and will be performed locally, in case that local guidelines is not available,  QuantiFERON TB gold test will be performed either locally or centrally . COVID -[ADDRESS_270922] IMP dose intake will be morning dose on -site on Day 85.  
j To use dipstick, if any abnormality, send sample to central lab for testing. Urine microscopic examination (including pyuria,  hematuria and urinary casts) and spot urine protei n/creatinine ratio test will be performed 
at Baseline, Week 12, and when the SELENA -SLEDAI is assessed.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270923] 4 days prior to baseline.  
p Sample collection : on Day 1, PK sampling within [ADDRESS_270924] morning dose (around C max); on Day [ADDRESS_270925] morning dose (around C max) and within 7 to 10 hours after the morning doses , On Day 85 (or early EOT) for all participants, PK sampling just before o r within [ADDRESS_270926] morning dose (around C max).  
q PBMC assay will be performed in patients with CLE in a subset of qualified sites.  
r Cytokine panel and chemokine panel assays will be performe d. Details of the assessment in the panels are provided in Section  8.6.  
s To be measured at V2 and as needed if suspi[INVESTIGATOR_225304] . 
t Only skin lesion to be biopsied. For patients wh o have no documented histological diagnosis, biopsy will be performed at screening and at Week 12. For patients who have docu mented histological diagnosis, 
biopsy will be performed at V2 after other eligibility assessments done and at Week 12. In case that  the patient is prematurely discontinued from IMP, biopsy will be performed at EOT instead of Week 12.  
u To be performed at the end of  treatment only, not required at Week 12 in case of premature end of treatment.
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 21 2 INTRODUCTION   
SAR443122 is a novel, potent and selective Receptor -Interacting serine -threonine Protein Kinase1 
(RIPK1) inhibitor for oral administration. RIP Kinase1 inhibition with SAR443122 results in the 
inhibition of tumor necrosis factor (TNF ), interferon (IFN ), toll -like receptor (TLR ) 3/4 mediated cell 
death (necroptosis or apoptosis) and inflammation triggered by [CONTACT_225350] -associated 
molecular patterns (DAMPs). SAR443122 has no effe ct on the scaffolding function of RIPK1 which 
is important for the Nuclear factor kB (NF -kB) dependent cell survival signaling downstream of the 
TNF-TNF receptor -1 complex. On the other hand, the RIP Kinase function involved in pro -
inflammatory signaling v ia pRIPK1/3 and pMLKL leading to membrane pore formation, cell death 
and DAMP release is inhibited by [CONTACT_13108]443122 (see SAR443122 Investigator Brochure for detailed 
information).  
In skin autoimmune disease, such as CLE, we hypothesize that RIPK1 inhibition wo uld be 
beneficial by a generalized dampening of the local pro -inflammatory milieu. CLE is manifested in 
the skin by [CONTACT_225351] -inflammatory cytokines as well as other mechanisms of cell 
death.  
Normally, controlled cell death is a physiologica l mechanism to remove infected or damaged cells 
but is also exploited by [CONTACT_225352]. Interferon receptors and TLR3/4 
receptors function as pathogen sensors of viral or bacterial components (PAMPs) or cell damage 
(DAMPs). Some pathogen s modulate pro -inflammatory response after TNF receptor stimulation 
to escape innate immunity. Similar to response to infection, this process appears to be involved in 
certain autoimmune diseases such as CLE.  
Interface dermatitis (ID), which includes most CLE forms, is characterized by [CONTACT_225353][INVESTIGATOR_225305]. Initial stimulus might be different among certain skin diseases, but dominance of 
cytotoxic T cells  and involvement of plasmacytoid dendritic cells are described in several ID 
positive skin diseases ( 6). Biopsy -derived T -cells from CLE patie nts are dominated by [CONTACT_225354] (IFN -γ) and tumor necrosis factor alpha (TNF -α) positive cells ( 7). It was also 
demonstrated that ID is  characterized by a shared transcriptome signature [CONTACT_225420] 
a strong type I immune response. RIPK1 gets activated downstream of TNF receptor and IFN 
receptor activation as well as TLRs. Hence, primary pro -inflammatory cytokines involved in th e 
pathophysiology of CLE are strongly linked to RIPK1 activation and downstream signaling 
demonstrated by [CONTACT_225355]1 signaling, phosphorylated RIPK1 (pRIPK1) and pMLKL 
(8). In conclusion, inhibition of RIPK1 downstream of TNF and IFN receptor activation are 
considered as a potential target to modulate the pathophysiology of CLE.  
Three -month toxicity studies of SAR443122 in monkey and rat  have shown no adverse events 
(AEs ) at the highest doses tested (  mg/kg/day and  mg/kg/day, respectively). In the 
3-month rat study, test article -related effects were limited to increases in mean body w eight, mean 
body weight gain, and mean food consumption for males administered  mg/kg/day; a few 
minor clinical pathology changes in animals administered ≥  mg/kg/day, with no microscopic 
correlates; microscopi[INVESTIGATOR_225306]-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 22 females administered ≥  mg/kg/day, with correlative splenic weight increases in females 
administered  mg/kg/day; increased liver weights for males administered  mg/kg/day 
and females administered ≥  mg/kg/day; and increased kidney weights for females 
administered ≥  mg/kg/day. All findings exhibited reversibility and were considered not 
adverse. Due to the mild severity of findings and the lack of impact on the health and well -being 
of animals administered  mg /kg/day, effects for this dose were considered non -adverse. Thus, 
the no observed adverse effect level (NOAEL ) is  mg/kg/day. This dose level corresponded 
to mean C max and AUC values of  µM and  h*µM, respectively, in males and  µM and 
 h*µM, respectively, in females during Week 13 of the dosing phase.  
In the 3 -month monkey study, non -adverse, SAR443122 -related, increases in the incidence and/or 
severity o f mononuclear cell infiltrates or increased lymphocytes were observed in multiple 
tissues of animals administered ≥  mg/kg/day. Many of the findings were not found after the 
recovery phase, indicating reversibility. However, increased incidences and/or se verities of 
mononuclear cell infiltrates persisted in the pancreas, lacrimal gland, kidney, sternum marrow 
(focal), tongue, and vagina. None of the findings in any dose group were considered adverse, thus, 
the NOAEL is  mg/kg/day. This dose level corres ponded to mean C max and AUC values of 
 µM and  h*µM, respectively, in males and  µM and AUC  h*µM, respectively, in 
females during Week [ADDRESS_270927] dosing. AUCs increased without major 
deviation from dose proportionality from  mg and then increased less than expected from 
dose proportionality from  mg. C max increased less than expected by [CONTACT_225356].  
After once daily repeated administration for 14 days, there is no drug accumulation. The mean 
elimination half -life was estimated between  hours. Concomitant intake of a high fat meal 
did not modify the bioavailability of SAR 443122 at 100 mg.  
Sustained maximal target engagement, measured as RIPK1 phosphorylation inhibition (>90%), was 
sustained for 24, [ADDRESS_270928] 72 hours after single doses of 100, 200 and 400 mg, respectively. 
During the multiple ascending dose (MAD ) study the median inhibition achieved during the period 
of maximal inhibition of the 50 mg group was 88.5% whereas the 100 and 200  mg groups show a 
median inhibition greater than 90% (93.9% and 91.3% res pectively). Duration of the period of 
maximal inhibition was longer in 100 and 200 mg groups (median: 58  hours and 65 hours 
respectively) than in 50 mg group (median: 22 hours) under multiple dosing.  
The favorable safety profile allows for high exposure wi th the opportunity to achieve high 
exposure (>IC90, over 24  h) in target cells of carefully selected indications. The projected AUC 
following 12 -weeks of administration to patients at 300 mg BID is  µM*h. Therefore, 
projected animal:human exposure ratio s based on AUC are 10X and 2.8X for the rat 3 -month and 
monkey 3 -month, respectively.  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270929] of the RIPK1 inhibitor SAR443122 in hospi[INVESTIGATOR_225307] -19 has started in July 2020.  
In Europe and the [LOCATION_003], the incidence of isolated CLE is ~4 cases per 100 000 persons per year, 
which is slightly higher than the incidence of SLE (~3 cases per 100 000 persons per year) ( 9, 10, 
11). CLE most often affects middle aged adults with a mean age at diagnosis of 54 years old. Skin 
involvement occurs in 70% -80% of all patients with SLE during th e course of their disease and 
skin lesions are the first disease manifestation to present in 20% -25% of patients with SLE ( 11). 
Patients with  CLE can progress to SLE with internal organ systems involvement. The rate of 
systemic manifestations depends on the underlying subtype of CLE; for example, acute cutaneous 
lupus erythematosus (ACLE) has the highest rate of systemic involvement (~90%), whe reas 
localized DLE has the lowest (<5%) ( 10, 12). 
All subtypes of cutaneous lupus can be triggered and worsened by [CONTACT_225357]. Acute CLE most 
often involves a prominent rash on the cheeks and nose (“butterfly rash”). Subacute CLE most 
often presents with an erythematous, scaly papules on sun -exposed areas of the body that evolve 
into plaques. It tends to have circular skin  lesions or lesions that can look like psoriasis on 
sun-exposed skin. Discoid lupus starts out as a red to purple scaly rash on the scalp, face, ears, and 
other sun -exposed areas. Over time, discoid lupus may heal with discolored scarring and even hair 
loss when the scalp is involved. Sometimes patients may feel pain or itch ( 13). Skin lesion can 
lead to permanent damage such as depi[INVESTIGATOR_371] a nd scarring if not treated. CLE skin 
manifestations in sun exposed area like scalp and face can be disfiguring and are a significant 
cause of morbidity.  
The adverse effects associated with exposure to UV light, in triggering and worsening disease 
activity,  protection from exposure to direct sunlight is recommended for all patients with 
cutaneous lupus; though photoprotection does not always work and is not always feasible. 
Additionally, reduced sun exposure results in a decreased activation of vitamin D and  the 
continuous or frequent use of corticosteroids increases the risk of osteoporosis. The guideline 
from the European Academy of Dermatology and Venereology recommends vitamin D 
supplementation for all patients with CLE to protect CLE patients against an increased risk of 
osteoporosis ( 14). 
Topi[INVESTIGATOR_225308] -line treatment for CLE lesions because of their anti -
inflammatory p roperties ( 14, 15). The pri mary indication for topi[INVESTIGATOR_225309] a localized 
DLE, patients with more extensive disease may show an inadequate response and are more prone 
to adverse effects. While topi[INVESTIGATOR_225310], 
they are frequently used as an alternative to topi[INVESTIGATOR_11930]. Unlike corticosteroids, these 
inhibitors do not induce skin atrophy, however, they are less effective than corticosteroids and 
carry a black box warning due to a potential tumor risk.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270930]-line treatment in patients with highly active or widespread lesions ( 14, 16). Antimalarial 
drugs (such as chloroquine, hydroxychloroquine and quinacrine) are the most frequently used 
systemic drugs in CLE. The mode of action of these relatively old antimalarial drugs is still under 
investigation, but all of th ese antimalarial drugs inhibit type I IFN production by [CONTACT_44859] -
activated peripheral blood mononuclear cells ( 17). Both chloroquine and hydrox ychloroquine are 
associated with important adverse drug reactions including QTc -prolongation and with long -term 
use there is a risk of potentially irreversible retinopathy.  
The use of systemic glucocorticoids (SGCs ) is recommended for severe or widespread active CLE 
lesions. However, to decrease the impact of adverse reactions associated with SGCs, there is an 
imperative to taper their use as soon as possible ( 14).  
In patients with long -standing disease or high disease activity, other immunosuppressive and 
immunomodulatory drugs such as methotrexate, retinoids and dapsone are used ( 15). 
Approximately 30% -40% of patients with CLE are refractory to antimalarials. Methotrexate is 
recommended for use in refractory CLE, primarily SC LE (13), dapsone for recalcitrant CLE and 
bullous lupus erythematosus, and retinoids for selected patients with CLE (particularly patients 
with hypertrophic DLE) when they are unresponsive to other treatments. All other drugs, 
including mycophenolate mofetil and cyclosporine, are considered third -line therapi[INVESTIGATOR_225311] ( 14). 
In summary, existing options to treat subacute and chronic cutaneous lupus are limited and the 
current mainstays of treatment are repurposed drugs with limited  evidence supporting their 
efficacy and are associated with considerable safety issues, in particular if used long -term.  
Patients using chloroquine and hydroxychloroquine for chronic treatment require regular 
ophthalmological screening to avoid potentially  irreversible retinopathies, which increase sharply 
after [ADDRESS_270931] been observed and may be underdiagnosed. Chronic use of oral 
corticosteroids has many serious adverse effects including osteoporosis, hypertension, diabetes, 
weight gain, increased vulnerability to infection, cataracts and glaucoma (eye disorders), and 
thinning of the skin. No drug has been specifically approved for the treatment of CLE and there is 
an unmet need for therapi[INVESTIGATOR_225312].  
2.2 BACKGROUND   
Preclinical data support the application of RIPK1 -inhibitors in ID, which includes CLE. Interface 
derm atitis characterized by [CONTACT_225358][INVESTIGATOR_49196], 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270932] of RIPK1 inhibition on 
preventing or attenuating cell death in ID. In these ongoing assays we aim to demonstrate that 
through RIPK1 inhibition, dysregulation of c ell death (apoptosis/necroptosis) is blocked and 
reduces overall inflammation.  
2.3 BENEFIT/RISK ASSESSM ENT  
The available nonclinical and clinical data from the SAR443122 developm ent program in healthy 
volunteers (78 receiving active drug) demonstrated that SAR443122 is well tolerated with a good 
safety profile to date. SAR443122 is proposed to target the chronic inflammation in participants 
with CLE which manifests as interface de rmatitis, namely DLE or SCLE. A dysregulated immune 
response to keratinocyte damage caused by [CONTACT_225359]. RIPK1 inhibition may prevent the damage 
inflicted on ker atinocytes and reduce the pro -inflammatory response to this damage, thereby 
[CONTACT_225360].  
More detailed information about the known and expected benefits and risks of SAR443122 may 
be found in the Investigator’s Brochure.  
2.3.[ADDRESS_270933] -in-human (FIH ) study 
(TDU [ZIP_CODE]/TDR16341). There were no serious adverse events (SAEs), no severe treatment -
emergent adverse events (TEAEs ) and no deaths. There were no relevant treatment emergent 
potentially clinic ally significant abnormalities (PCSAs ) for the laboratory values, vital signs, and 
ECG parameters.  
TDU16339 Part 1a single dose ascending (SAD):  Total of  healthy volunteers were enrolled: 
 subjects were enrolled into each of the , and treated with  mg,  mg,  mg, 
 mg,  mg or  mg of SAR443122 (or placebo), respectively. No adverse events of 
special interest (AESIs), or t reatment related TEAEs leading to treatment discontinuation reported 
during the study.  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270934] and relative bioavailability study:  Total of  healthy volunteers 
completed all three periods. There were no AESIs, or treatment related TEA Es leading to 
treatment discontinuation reported during the study.  
TDR16341 -Part2 -MAD:  Total of  healthy volunteers randomized and treated: Placebo: ; 
SAR443122  mg: ; SAR443122  mg: ; SAR443122  mg: ; SAR443122  mg: . 
Treated  day s with highest multiple dose at  mg QD x  days.  
• Two AESI of alanine transaminase (ALT ) elevation >2 x upper limit of normal (ULN ), but 
<[ADDRESS_270935] on immune system and anemia.  
Table  1 - Risk assessment   
Potential risk of clinical 
significance  Summary of data/rationale for 
risk Mitigation strategy  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 27 Potential risk of clinical 
significance  Summary of data/rationale for 
risk Mitigation strategy  
2.3.2  Benefit assessment   
Currently, there are no approved drugs for CLE. Limited existing options including antimalarial 
drugs, glucocorticoids, immunosuppressants and immunomodulators are often tried. All these 
drugs are repurposed drugs with limited evidence supporting their efficacy and with considerable 
side-effects. There is a high unmet m edical need in patients with moderate to severe CLE.  
Through RIPK1 kinase inhibition, SAR443122 is expected to inhibit the dysregulation of 
apoptosis/necroptosis observed in ID including CLE and downregulate the inflammation. Based 
on the mechanism of acti on, and even though the study is of short duration, the potential benefits 
would be:  
• Reduction in disease activity score (CLASI -A) 
• Reduction in itch  
• Reduction in pain  
• Reduction of cutaneous or systemic disease flares  
• Reduction in oral or genital lesions  
• Improvement in QoL  
2.3.3  Overall benefit: risk conclusion   
Based on the FIH clinical studies (TDU16339/TDR16341) SAR443122 was safe and well 
tolerated in healthy volunteers up to  mg given as a single dose and up to  mg given daily 
for  days. SAR443122 has demonstrated a satisfactory safety profile in the nonclinical toxicity 
studies and was not found to be genotoxic or phototoxic.  The projected AUC following -weeks 
of administration to patients at  mg BID is  µM*h. Therefore, projected animal:human 
exposure ratios based on AUC are X and X for the rat -month and monkey -month, 
respectively.  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 28 Risk management procedures and specific safety monitoring in particular to mitigate the potential 
risk of immune system disorder or anemia will be implemented ( Section  2.3.1 ). 
Based on the acceptable safety profile summarized above and the potential for considerable 
benefits on cutaneous lupus disease activity, on acute epi[INVESTIGATOR_225313] -term sequelae, the 
potential benefits outweigh the risks in the proposed study population.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 29 3 OBJECTIVES AND ENDPO INTS   
Table  2 - Objectives and endpoints   
Objectives  Endpoints  
Primary  
• Assess the efficacy of SAR443122 in CLE  • Percent change from baseline in Cutaneous 
Erythematosus Disease Area and Severity Index 
activity (CLASI -A) sub -score at Week 12  
Secondary  
• Assess the effect of SAR443122 on the physician’s 
global assessment of disease activity 
(PhysGA - disease activity)  • Proportion of patients with PhysGA - disease 
activity of 0 or 1 (disease free or almost disease 
free) at Week 12  
• Assess the effect of S AR443122 on CLE induced 
itch and overall pain  • Change from baseline in patients reported daily 
worst itch using Peak Pruritus Numerical Rating 
Scale (itch -NRS) at Week 12  
• Change from baseline in patients reported daily 
worst pain using Peak Pain Numerical Rating 
Scale (Pain -NRS) at Week 12  
• Assess the effect of SAR443122 on the proportion 
of disease activity responders compared to 
placebo  • Proportion of CLASI -A50 and CLASI -A75 
responders at Week 12  
• Assess the effect of SAR443122 on the CLASI  
components’ score  • Change from baseline in CLASI components' score 
over time  
• Assess the effect of SAR443122 on the 
Investigator’s global assessment for CLE (IGA -
CLE)  • Proportion of patients with IGA -CLE score of 0 or 1 
(clear or almost clear) at Week  12 
• Assess oral cavities for patients with oral lesions  • Change from baseline to Week [ADDRESS_270936] Profile (OHIP -14) for patients with 
oral lesions at baseline  
• Assess the disease specific quality of life (QoL)  • Change from baseline in SKINDEX -29+3 total 
score at Week 12  
• Assess the safety and tolerability of SAR443122 in 
patients with CLE  • Total number and percent of treatment -emergent 
adverse events (TEAEs), serious adverse events 
(SAEs), adverse events of special interest (AESIs)  
• Percent of potentially clinically significant 
abnormalities (PCSAs) in laboratory tests, 
electrocardiogram (ECG) or vital signs through end 
of study (EOS)  
• Assess the pharmacokinetics (PK) exposure of 
SAR443122 in patients with CLE  • SAR443122 plasma concentration  
• Pharmacokinetic parameters (maximum 
concentration [C max], time to C max [tmax], area under 
the curve over the dosing interval [AUC 0-tau], and 
elimination half -life [t 1/2z]) 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022
Version number: 1
Property of the [COMPANY_011] group - strictly confidential  Page 30 Objectives  Endpoints  
Exploratory  
• Assess the effect of SAR443122 on physicians’
and patients’ overall impression of change of the
disease activity and of the severity, and specific
domains of health -related QoL• Change from baseline at Week 12 in each of the
sub-scores of the SKINDEX -29+3
• Change from baseline at Week 12  in the patient's
global impression of disease severity (PGIS)
• Evaluation of patient's global impression of change
(PGIC) in overall disease at Week 12
• Evaluation of physician's global assessment of
change in disease activity (PhysGAC disease
activity)  at Week 12
• Assess the effect of SAR443122 on CLE related
joint inflammation• Change from baseline in active joint count
assessment (28 joint assessment) at Week 12
• Assess the effect of SAR443122 on reducing
systemic lupus erythematosus activity• Change from baseline in Safety of Estrogens in
Lupus Erythematosus National Assessment -
Systemic Lupus Erythematosus Disease Activity
Index (SELENA -SLEDAI) over time
• Change from baseline in transcriptomic biomarkers
from mRNA derived from skin biopsy  and from
blood
• Change from baseline of blood plasma biomarkers
(eg, cytokine and chemokine levels) over time
• Demonstrate inhibition of pS166 -RIPK1 in PBMC
lysates with SAR443122 treatment compared to
placebo in a subset of patients at Week 12
• Change from baseline to Week 12 in Genital
Erosive Lichen Planus (GELP) total score for
female patients with genital lesions at baseline
• Photographic assessment of index lesions (Central
imaging acquisition tool), oral lesions if present
• Histologic changes in skin biopsies (Central
pathologist)• Assess the effect of SAR443122 on RNA  
expression levels from skin biopsy and from blood 
as an indicator of response/disease progression
• Assess the effect of SAR443122 on biomarkers in  
blood plasma (eg, cytokine and chemokine levels)  
as an indicator of response/disease progression
• Assess target engagement of SAR443122 as a 
function of RIPK1 kinase activity/inhibition  achieved 
by [CONTACT_13108]443122 in peripheral blood  mononuclear 
cells (PBMCs) of patients with CLE in a subset of 
qualified sites
• Assess the genital area for female participants  with 
genital lesions
• Assess the effect of SAR443122 on skin lesion by 
[CONTACT_225361], oral  
lesions if present
• Exploration of histologic changes in skin biopsies
• Assess the effect of SAR443122 on the use of  
rescue medication• The frequency of use of rescue medications by
[CONTACT_17203] (eg, topi[INVESTIGATOR_11930], topi[INVESTIGATOR_225314], oral corticosteroids)
3.1 APPROPRIATENESS OF MEASUREMENTS  
The Cutaneous Erythematosus Disease Area and Severity Index (CLASI ) is a validated clinical 
instrument with documented content validity and good psychometric properties (inter - and intra - rater 
reliability; ability to detect changes) ( 2, 18, 19, 20, 21). It is commonly used clinically to assess 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 31 disease activity (CLASI -A) and skin damage (CLASI -D) induced by [CONTACT_225362]. The primary endpoint is 
to assess disease activity; measured by [CONTACT_225363] -A sub -score. This choice is in line with the 
standard instrument for evaluation of disease activity and the study design publicly available.  
To assess changes in skin lesions and potential early skin lesion improvement, the change of 
CLASI individual components from baseline will be evaluated, which occurs typi[INVESTIGATOR_225315].  
As a secondary endpoint, overall disease act ivity will be assessed by [CONTACT_78616] -CLE. The IGA is 
widely used in several dermatological conditions with verbal descriptors specific for the 
assessment of the indication in which it is used. The IGA -CLE is under development to be 
specific for the assessment  of CLE by [CONTACT_225364].  
The 5 point -lickert scale Physician’s Global assessment of disease activity (PhysGA -disease 
activity) will provide a global evaluation of the disease activity as per investigator’s evaluation. 
This inst rument will be a secondary endpoint.  
Numerical rating scale (NRS) is one of standard measurement instruments for evaluation of 
chronic symptoms and is a popular choice for all patients due to its simple format. The peak 
pruritus NRS (itch -NRS ) assess worst itch in the past 24 hours features high reliability and 
concurrent validity. The peak pain NRS (pain -NRS ) related to CLE is developed specifically for 
this study and will assess worst pain related to CLE in the past 24 hours.  
GELP score is a scoring system for clinical assessment of genital lesions in women and it has 
been developed in lichen planus. For both t he targeted CLE subtypes of the present study and 
lichen planus (LP ) manifest interface dermatitis, CLE patients may present oral and/or genital 
lesions. These two clinical instruments validated in LP are consi dered as appropriate to assess oral 
and/or genital lesions in CLE patients. The results obtained from this study can serve for the 
larger study in CLE in the future.  
As an exploratory endpoint, [ADDRESS_270937] on joint involvement in CLE patients in this study.  
Safety of Estrogens in Lupus Erythematosus National Assessment -SLE Disease Activity Ind ex 
(SELENA -SLEDAI ) is an instrument for the assessment of systemic manifestations of lupus ( 22). 
It is a clinical instrument to assess the disease activity in patients with SLE. In the present study, 
SLE patients without major organ involvement will be allowed to participate, and C LE could 
progress to SLE in some patients. It is anticipated to administer the SELENA -SLEDAI in all 
patients enrolled in order to monitor the lupus disease activity and potential development of 
systemic disease. Potential effect of SAR443122 on the systemi c manifestations of lupus will be 
explored with this instrument.  
A quality of life questionnaire Skindex 29+3 (also called SkindexLupus) ( 5) will evaluate the 
effect of SAR443122 on patient’s QoL. It includes Skindex -29 items and a set of 3 questions to 
assess lupus -specific issues, ie, photosensitivity and alopecia.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 32 Patient’s global impression of disease severity (PGIS ) instrument will evaluate patient -reported 
impression of the disease severity while patient’s global impression of change in disease activity 
(PGIC ) and physician’s global assessment of change in disease activity (PGAC ) will evaluate 
patients and physicians evaluation of change in diseas e since the start of study medication, 
respectively. These scales will be used as anchor measure to validate psychometric properties of 
CLASI and patient reported outcomes (PROs ) assessments used i n the study.  
The pharmacokinetic assessments used in this study are standard for the evaluation of the drug 
administrated BID.  
The exploratory assessments related to DNA, RNA and biomarkers are selected based on the 
current knowledge from the literature an d in-house research.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270938] significant involvement of the central nervous system 
(CNS), lung or kidney such as lupus nephritis.  
The study will be blinded to investigators, patients and [COMPANY_011] as well as [COMPANY_011] contracted staff.  
Participants will be randomized in a ratio of 1:1 to either SAR443122 or placebo arm. The 
randomization will be stratified by [CONTACT_225344] (DLE or SCLE), baseline use of chloroquine 
or hydroxychloroquine, and by [CONTACT_11338]. Up to [ADDRESS_270939] an up to 4 weeks screening period to assess the eligibility, 12 weeks 
treatment period counting from the day of randomization (Baseline, Day 1) and a [ADDRESS_270940] a 
documented histological diagnosis of CLE within 1 year prior to Screening, biopsy will be performed 
at Baseline, the eligibility related to CLE diagnosis will be based upon the documented result.  
During the 12 weeks treatm ent period, participants will be assessed by [CONTACT_225345] 
4 weeks and undergo a series of clinical laboratory examinations for efficacy, safety, 
pharmacokinetic, pharmacodynamic and exploratory assessments. Patient reported daily disease 
symptoms (i tch and pain) will be assessed on a daily basis within two weeks and at least 4  days 
prior to baseline and during treatment period. Details can be found in Section  1.3. 
The primary objective of the study is to assess disease activity compared with placebo at Week 12 
as measured by [CONTACT_225363] -A sub -score, the Cutaneous Lupus Erythematosus Disease Area and 
Severity Index ( 2, 3) activity sub -score. The secondary endp oints include IGA -CLE score, 
PhysGA - disease activity at Week 12, assessments of CLE -induced itch and pain evaluated 
separately daily by a patient reported NRS, the comparison of CLASI -A50, CLASI -A75 
responder rate, and  change from baseline of CLASI indivi dual components score ( 4). The safety 
of SAR443122 will be assessed throughout the study. A quality of life instrument 
SKINDEX -29+3 will be used for quality of life assessment ( 5). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 34 During the study, the rescue medication may be used in case of CLE worsening per investigator’s 
medic al judgement. If feasible, rescue medication should not be used for at least [ADDRESS_270941] administration of study intervention. Details can be found in Section  6.8.8 . 
An internal safety review committee (ISRC) will be established to oversee the welfare of the 
participants as well as the safety, scientific integrity of the trial. Details regarding the 
composition, mandate and function of the internal safety review committee will be provided in the 
respective charter.  
4.2 SCIENTIFIC RATIONALE  FOR STUDY DESIGN   
This Phase 2a study is designed as a pr oof-of-concept study aimed at evaluating efficacy and 
safety of RIPK1 kinase inhibitor SAR443122 in patients with moderate and severe CLE 
(CLASI -A ≥10).  
The target population are patients with CLE which manifest interface dermatitis, namely DLE or 
SCLE bas ed upon the hypothesis that RIPK1 inhibition may prevent the damage inflicted on 
keratinocytes and reduce the pro -inflammatory response to this damage, thereby [CONTACT_225365].  
The proposed [ADDRESS_270942] in 
patients with CLE.  
Existing options for  treatment of CLE are repurposed drugs with limited evidence supporting their 
efficacy and with considerable safety issues. A placebo -controlled and parallel arms study is 
appropriate to evaluate efficacy and safety of SAR443122 in this population. PK and various 
biomarkers will be evaluated in this early clinical development study as well.  
This study is double -blind to minimize potential for bias on the part of the investigator, 
participant, or sponsor.  
The randomization ratio is 1:1. Stratification by [CONTACT_225366], baseline use of chloroquine or 
hydroxychloroquine (yes/no), and by [CONTACT_225367], background treatment and seasonality on the 
participant’s response to the study treatment.  
Given that the study is placebo -controlled and is the first study of SAR443122 in patients with 
CLE, during the study, rescue medication may be used, to mitigate any potential risk related to 
CLE worsening.  
An Internal Safety Review Committee which is independent to study team will oversee the 
welfare of the participants as well as adverse drug effects.  
While there is no formal statistical hypothesis testing performed, the sample size was derived with 
respect to the primary endpoint ( see Section  9.1). Thus, it is anticipated that the current sample 
size of approximately [ADDRESS_270943] ion of disease activities in 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270944] not been involved in the design of this clinical trial.  
4.3 JUSTIFICATION FOR DO SE  
Recently released clinical data from a competitor ( 23) and internal p reclinical data in chronic 
inflammatory CNS disease, suggest that very high levels of RIPK1 kinase activity inhibition are 
required to have a clinical effect and that exposure needed to reach this high level of inhibition is 
higher in chronic inflammatory disease than in healthy subjects. Therefore, a daily dose of [ADDRESS_270945] completed the study if he/she has completed all phases of the 
study including the last visit (End of Study visit, EOS) as shown in the Schedule of Activities 
(Section  1.3). 
The end of the study is defined as the date of the last visit of the last participant in the study 
globally.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 36 5 STUDY POPULATION   
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exem ptions, is not permitted.  
5.1 INCLUSION CRITERIA   
Participants are eligible to be included in the study only if all of the following criteria apply:  
Age 
I 01. Participant must be 18 to 80 years of age inclusive, at the time of signing the informed 
consent  
Type of participant and disease characteristics  
I 02. Participants with cutaneous lupus erythematosus either in the form of discoid/chronic 
cutaneous lupus erythematosus or subacute cut aneous lupus erythematosus for at least 
3 months before Screening  
I 03. Participants with hi stologically confirmed and documented diagnosis within one year prior 
to Screening or during Screening period prior to randomization  
I 04. Active cutaneous lupus erythematosus skin lesions and a CLASI -A ≥10 both at Screening 
and Baseline  
I 05. Participant who is candidate for systemic treatment per Investigator’s judgement    
Sex, contraceptive/barrier method and pregnancy testing requirements  
I 06. All 
Contraceptive use by [CONTACT_225368].  
a) Male participants  
Male participants are eligible to participate if they agree to the following during the 
study interventi on period and for at least [ADDRESS_270946] dose of IMP, corresponding 
to time needed to eliminate study intervention(s) (eg, 5 terminal half -lives)  
• Refrain from donating sperm.  
PLUS, either : 
• Be abstinent from heterosexual intercourse as their prefer red and usual lifestyle 
(abstinent on a long term and persistent basis) and agree to remain abstinent.  
OR 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 37 • Must agree to use contraception/barrier as detailed below  
- A male condom and an additional highly effective contraceptive method as 
described in Appendix 4 Contraceptive and barrier guidance ( Section  10.4) when 
having sexual intercourse with a woman of childbearing potential (WO CBP) who 
is not currently pregnant.  
b) Female participants  
A female participant is eligible to participate if she is not pregnant or breastfeeding, and 
one of the following conditions applies:  
• Is a woman of non -childbearing potential (WONCBP) as defined in Appendix 4 
Contraceptive and barrier guidance (Section  10.4). 
OR 
• Is a WOCBP and agrees to use a contraceptive method that is highly effective (with 
a failure rate of <1% per year ), preferably with low user dependency, as described in 
Appendix 4 Contraceptive and barrier guidance (Section  10.4) during the study 
intervention period and for at least 2 days,  corresponding to the time needed to 
eliminate any study intervention(s) (eg, 5 terminal half -lives) plus 30 days (a menstrual 
cycle) after the last dose of study intervention and agrees not to donate eggs (ova, 
oocytes) for the purpose of reproduction during this period . 
- A WOCBP must have a negative highly sensitive pregnancy test ( urine and/or 
serum  as required by [CONTACT_427] ) at Screening and Baseline visits before 
the first administration  of study intervention, see Section  10.[ADDRESS_270947] cannot be confirmed as negative (eg, an ambiguous result), a serum 
pregnancy test is required. In such cases, the participant must be excluded from 
participation if the serum pregnancy result is positive.  
c) Local  regulations regarding  contraception for male and female participants 
(see Section  10.4.2 ). 
Informed Consent  
I 07. Capable of giving signed informed consent as described in Appendix 1 ( Section  10.1) of 
the protocol which includes compliance with the requirements and restrictions listed in t he 
informed consent form (ICF) and in this protocol. In countries where legal age of majority 
is above [ADDRESS_270948] also be signed by [CONTACT_2299]’s legally authorized 
representative.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 38 5.2 EXCLUSION CRITERIA   
Participants are excluded from the study if any of the following criteria apply:  
Medical conditions  
E 01.  Systemic lupus erythematosus according to the 2012 SLICC criteria ( 24) with major organ 
involvement such as lupus nephritis, cardiopulmonary involvement (eg, interstitial lung 
disease, pulmonary hypertension, pleuritis,  pericarditis, myocarditis, and endocarditis), 
neuropsychiatric involvement, vasculitis, antiphospholipid syndrome (APS) on or 
requiring chronic anticoagulation, significant hematological and/or gastrointestinal 
involvement. Concurrent findings of malar ra sh, constitutional symptoms, alopecia, 
arthralgia/arthritis, myalgia, oral/nasal ulcers, Sjogren syndrome, Raynaud's phenomenon, 
sub-clinical pericardial and/or pleural effusions are permitted. Please consult the Sponsor 
for related SLE manifestations if u nclear related to eligibility.  
E 02.  Suspected or proven drug induced lupus erythematosus, including patients with positive 
antihistone autoantibody tests.  
E 03.  Diagnosed with certain subtypes of CCLE (such as Lupus erythematosus tumidus, 
Chilblain, lupus panniculiti s, lichenoid cutaneous lupus/lichen planus overlap syndrome).  
E 04.  Autoimmune disease(s) other than systemic lupus erythematosus (eg, systemic sclerosis, 
myositis, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, 
multiple sclerosis, Behcet’s disease etc).  
E 05.  Active skin diseases that may interfere with the study or study assessments (eg, Psoriasis).  
E 06. History of significant cardiovascular diseases/conditions, clinically significant renal, hepatic, 
metabolic (eg , poorly controlled diabetes mellitus demonstrated by [CONTACT_225369]1 ≥9%), 
neurologic, hematologic, ophthalmologic, respi[INVESTIGATOR_696], gastrointestinal, cerebrovascular or 
other significant medical illness or disorder which, in the judgment of the Investigator, could 
interfere with the study or require treatment that might interfere with the study.  
E 07.  History of any malignancy except history of adequately treated basal cell carcinoma or in 
situ cervical carcinoma.  
E 08. Patients with active tuberculosis (TB) or non-tuberculous mycobacterial infection, or a history 
of incompletely treated active or latent TB per local guidelines will be excluded from the 
study unless it is documented by a specialist that the participant has been adequately treated 
and can now star t treatment with the RIPK1 kinase inhibitor. Also excluded from the study 
are patients with a positive [COMPANY_003] test, Mantoux test or Quantiferon -TB Gold test at Screening 
indicating latent tuberculosis or another mycobacterial infection. Positive [COMPANY_003] or Mantou x is 
acceptable if can be explained by a documented BCG -vaccination. The method of 
tuberculosis testing will be selected on a country -by [CONTACT_225370], according to local 
guidelines. If Quantiferon -TB Gold test is used as per local guidelines, patients wit h positive 
or 2 confirmed indeterminate Quantiferon -TB Gold tests at screening (regardless of prior 
treatment status) will be excluded.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 39 E 09.  History of HIV infection or positive HIV serology at screening.  
E 10.  Participants with any of the following result at screeni ng: 
- Positive (or indeterminate) HBs Ag or,  
- Positive total HBc Ab confirmed by [CONTACT_125447],  
- Positive HCV Ab.  
E 11.  History of recurrent or recent serious infection (eg , pneumonia, septicemia) within 4 weeks 
of screening, infection requiring hospi[INVESTIGATOR_5186] n or intravenous antibiotics, antivirals or 
antifungals within 4 weeks of screening or chronic bacterial infections deemed 
unacceptable, as per Investigator’s judgement.  
E 12.  Recurrent or active herpes zoster within 2 months prior to screening.  
E 13.  Prolonged QTcF  ≥450 ms (by [CONTACT_225371] ) or clinically significant findings on ECG 
per Investigator's assessment at Screening or during Screening period . 
E 14.  Exposure to another investigative drug (monoclonal antibodies as well as small molecules) 
prior to Visit 1, with in the period specified as follows: an interval of less than 6 months or 
<5 PK half -lives for investigative monoclonal antibodies, and an interval of less than 
30 days or <[ADDRESS_270949], suspected of COVID -19 infection or known exposure 
to COVID -19 during the screening period.  
E 17.  History of COVID -19 infection  within 4 weeks prior to Screening; history of mechanical 
ventilation or extracorporeal membrane oxygenation (ECMO) due to COVID -19 infection 
within 3 months prior to Screening or with residual significant complications from 
COVID -19 making it unsafe for t he participant to enter this study.  
E 18.  Cannot avoid excessive UV exposure (such as use of tanning equipment and/or sun 
exposure [eg , beach vacation]) 4 weeks prior to baseline and during the study. Routine sun 
exposure through work (eg , farmer, construction w orker, etc) are permitted but requires the 
use of sun block (recommend to use sun block with SPF 50 or higher) to sun exposed areas 
for at least 4 weeks prior to baseline and during the study . 
Prior/concomitant therapy  
E 19.  Concomitant treatment with topi[INVESTIGATOR_225316] a stable regimen of low 
to medium potency topi[INVESTIGATOR_40826]/or topi[INVESTIGATOR_225317].  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 40 E 20.  Initiation and/or changes in dosage of chloroquine/hydroxychloroquine wi thin 12 weeks 
prior to Screening visit (or during Screening period) and/or the dose exceeding 
2.3 mg/kg/day for chloroquine or 400  mg/day for hydroxychloroquine.  
E 21.  Systemic treatments (except for the study medication) for cutaneous or systemic lupus 
erythema tosus or immunosuppressive therapy for autoimmune disease other than the study 
medication including:  
- cyclosporin and dapsone within 4 weeks prior to baseline visit.  
- methotrexate within 6 weeks prior to baseline visit.  
- mycophenolate mofetil (MMF), thalidom ide, azathioprine, systemic retinoids, 
belimumab as well as any anti -TNF mAbs, B and/or T cell targeted 
immunosuppressive therapi[INVESTIGATOR_6523] [ADDRESS_270950] eroids treatment <4 weeks before baseline visit.  
E 23.  Live vaccine(s) within 1 month prior to Screening, or plans to receive such vaccines during 
the study.  
Prior/concurrent clinical study experience  
E 24.  Participation in another clinical study 60 days before baseline visit.  
Diagnostic assessments  
E 25.  Any of the following laboratory abnormalities at the Screening visit:  
- Hemoglobin <10 g/dL . 
- Absolute neutrophil count (ANC) <1500 /mm3 (or <1000/mm3 for participants of 
African descent).  
- Platelet <100 000 /mm3. 
- Creat inine clearance <60 mL/min using Cockcroft -Gault equation . 
- ALT or AST or ALP >1.[ADDRESS_270951] . 
- Total bilirubin >1.[ADDRESS_270952] or total bilirubin between > ULN and ≤1.[ADDRESS_270953] and 
associated with > ULN conjugated bilirubin unless documented Gilbert's syndrome . 
Retest ca n be done to reassess the eligibility during Screening period as per investigator's 
judgement that observed abnormality is not clinically significant and not consistent with 
patient's medical history . 
Other exclusions  
E 26.  Individuals accommodated in an insti tution because of regulatory or legal order; prisoners 
or participants who are legally institutionalized.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 41 E 27.  Any country -related specific regulation that would prevent the participant from entering 
the study - see Appendix 8 of the protocol  (Section  10.8 country -specific requirements) . 
E 28.  Individuals with established dependency on drugs or alcohol, per the judgement of the 
investigator.  
E 29.  Participant not suitable for participation, whatever the reason, as judged by [CONTACT_3786], including medical or clinical conditions, or participants potentially at risk of 
noncompliance to study procedures . 
E 30.  Participants are employees of the clinical s tudy site or other individuals directly involved 
in the conduct of the study, or immediate family members of such 
individuals  (in conjunction with Section 1.61 of the ICH -GCP Ordinance E6).  
E 31.  Any specific situation during study implementation/course that may  rise ethics 
considerations . 
E 32.  Sensitivity to any of the study interventions, or components thereof, or drug or other 
allergy that, in the opi[INVESTIGATOR_689], contraindicates participation in the study . 
 
5.3 LIFESTYLE CONSIDERAT IONS   
5.3.1  Meals and dietary restrictions   
No restrictions are required.  
5.3.2  Caffeine, alcohol, and tobacco   
The information of one’s regular use of alcohol and tobacco should be recorded in eCRF.  
5.3.3  Activity   
Not applicable.  
5.4 SCREEN FAILURES   
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assigned to study intervention.  A minima l set of screen failure 
information is required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond 
to queries from regulatory authorities. M inimal information includes demography, screen failure 
reasons, eligibility criteria, and any serious adverse event (SAE ). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 42 Individuals who do not meet the criteria for participation in this study (scre en failure) may be 
rescreened [ADDRESS_270954] be repeated except biopsy done in previous screening visit. There is no 
requirement for a waiting period between the screen failure date and the rescreen date.  
5.5 CRITERIA FOR TEMPORA RILY DELAYI NG 
(ENROLLMENT/RANDOMIZA TION/ADMINISTRATION OF STUDY INTERVENTION )  
During  a regional or national emergency declared by a governmental agency, if the site is unable 
to adequately follow protocol mandated procedures, contingency measures are proposed in 
Appendix 9 ( Section  10.9): Contingency measures f or a regional or national emergency that is 
declared by a governmental agency should be considered for screening, enrollment, 
randomization, and administration of study intervention . 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 43 6 STUDY INTERVENTION(S ) AND CONCOMITANT TH ERAPY   
Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, 
or medical device(s) intended to be administered to a study participant according to the study 
protoc ol. 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 44  
6.1 STUDY INTERVENTION(S ) ADMINISTERED   
6.1.[ADDRESS_270955]   
Table  3 - Overview of study interventions administered   
Arm name  [CONTACT_13108]443122  Placebo  
Intervention labels  SAR443122  Placebo  
Type  Drug  Drug  
Dose formulation  Capsules  Capsules  
Unit dose strength(s)  100 mg  N/A 
Dosage level(s)  3 capsules (300 mg) BID  3 capsules BID  
Route of administration  Orala Oral 
Use Experimental  Placebo  
IMP or NIMP  IMP IMP 
Packaging and labeling  IMP will be provided in double blind kit labeled as required per 
country requirement  IMP will be provided in double blind kit labeled as required per 
country requirement  
[Current/ Former  name(s) or alias(es)]  DNL758  Not applicable  
a The IMP can be taken with or without food.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 45 The SAR443122/placebo may be supplied at the site or from the PI/site/Sponsor to the participant 
via a Sponsor -approved courier company where allowed by [CONTACT_225372].  
For a regional or national emergency declared by a governmental agency that results in travel 
restrictions, confinement, or restricted site access, contingency measures are included in  
Appendix  9 (Section  10.9): Contingency Measures for a regional or national emergency that is 
declared by a governmental agency.  
6.1.[ADDRESS_270956]   
Rescue treatment may be used per investigators’ judgement during the study. Topi[INVESTIGATOR_225303]/or topi[INVESTIGATOR_125039]/or one short course of oral corticosteroids 
of up to 10 days ar e allowed. Initiation of any new topi[INVESTIGATOR_40826]/or topi[INVESTIGATOR_225318]/or increase potency, or initiation of oral corticosteroid for treating CLE 
will be considered a rescue treatment.  
If other systemic rescue medications such as immunosuppressants are required (except initiation 
or increase the dose of chloroquine or hydroxychloroquine), the patient should be permanently 
discontinued from the study drug but they should be encouraged to stay in the study until the end 
of the stu dy. 
6.1.3  Devices   
Not applicable.  
6.2 PREPARATION/HANDLING /STORAGE/ACCOUNTABIL ITY  
1. The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention.  
2. Only participants enrolled in the study m ay receive study intervention and only authorized 
site staff may supply or administer study intervention. All study intervention must be 
stored in a secure, environmentally controlled, and monitored (manual or automated) area 
in accordance with the labeled  storage conditions with access limited to the Investigator 
and authorized site staff.  
3. The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record  maintenance 
(ie, receipt, reconciliation, and final disposition records).  
Any quality issue noticed with the receipt or use of an IMP  (deficiency in condition, appearance, 
pertaining documentation, labeling, expi[INVESTIGATOR_320], etc)  must be promptly notified  to the Sponsor. 
Some deficiencies may be recorded through a complaint procedure (see Section  8.3.9 ). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270957] party (except for DTP 
shipment, for which a courier company has been approved by [CONTACT_1034]), allow the IMP to be 
used other than as directed by [CONTACT_13129], or dispose of IMP in a ny other manner.  
6.3 MEASURES TO MINIMIZE  BIAS: RANDOMIZATION  AND BLINDING   
Methods of assigning participants to treatment arm  
The randomized treatment kit number list is generate d centrally by [CONTACT_13225].  
The IMPs are packaged in accordance with this list.  
All participants will be centrally assigned to randomized study intervention using an interactive 
response technology (IRT). The [COMPANY_011] Clinical Supply Chain team will provide the r andomized 
treatment kit number list to the IRT. The IRT system generates the participant randomization list 
and allocates the intervention number and the corresponding treatment kits to the participants 
according to it.  
The Investigator or designee will ob tain the treatment kit numbers at randomization (Day 1, 
Baseline) and subsequent scheduled dosing visits via IRT that will be available 24 hours/day. 
Although the kit numbers will vary for the individual participant, the treatment group assignment 
and rand omization will not change throughout the study.  
Treatment kits will be dispensed at the study visits summarized in SoA ( Section  1.3). Returned 
study treatment kits should not be re -dispensed to the participants.  
Participants will be randomized in 1:[ADDRESS_270958] on Baseline/Day 1 and will be stratified by [CONTACT_225344] (DLE 
versus SCLE), baseline use of chloroquine or hydroxychloroquine (Yes versus No), and by 
[CONTACT_11338]. Sub -type of CLE and baseline use of chloroquine or hydroxychloroq uine will be entered 
in the IRT before randomization takes place.  
A participant cannot be randomized more than once in the study.  
Methods of blinding and code breaking during the study  
SAR443122 100 mg and matching placebo will be provided in identically a nd visually 
indistinguishable capsules.  
The investigator, other staff members, as well as the participant will remain blinded and will not 
know the participant’s intervention assignment during the study.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 47 • The IRT will be programmed with blind -breaking instr uctions. In case of an emergency, 
the Investigator has the sole responsibility for determining if unblinding of a participant’s  
intervention assignment is warranted (eg, in case of available antidote). Participant safety 
must always be the first considerat ion in making such a determination. If the Investigator 
decides that unblinding is warranted, he/she may, at his/her discretion, contact [CONTACT_225373] a participant’s intervention assignment unless 
this could dela y emergency treatment of the participant. If a participant’s intervention 
assignment is unblinded, the Sponsor must be notified within [ADDRESS_270959] igator or designee, under medical supervision. The date and time of each dose administered 
in the clinic will be recorded in the source documents and patient’s e -Diary. The dose of study 
intervention and study participant identification will be confirmed a t the time of dosing by 
a member of the study site staff other than the person administering the study intervention.  
When participants self -administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. IMP kit s are delivered by [CONTACT_225374] -site 
visits for the following 4 weeks administrations at home. IMP kits (used, unused and partially 
used) are returned by [CONTACT_21439]. In case of DTP process, the IMP kits can be 
provided and retu rned by [CONTACT_21440] (if defined in the contract). Compliance will be assessed by 
e-Diary records and counting returned capsules during the site visits and documented in the source 
documents and eCRF . Deviation(s) from the prescribed dosage regimen should b e recorded in the 
eCRF.  
A record of the number of SAR443122/placebo capsules dispensed to and taken by [CONTACT_225375]. 
Intervention start and stop dates , including dates for  intervention delays and/or dose reductions 
will also be recorded in the CRF.  
6.5 DOSE MODIFICATION   
Not applicable for this study.  
6.5.1  Retreatment criteria   
Not applicable.  
6.6 CONTINUED ACCESS TO INTERVENTION AFTER T HE END OF THE STUDY   
Not applicable.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 48 6.7 TREATMENT OF OVERDOSE   
Sponsor does not recommend specific treatment for an overdose.  
In the event of an overdose, the Investigator should assess the participant, and then:  
1. Contact [CONTACT_27465].  
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities until 
SAR443122  can no longer be detected systemically (at least  5 days).  
3. Obtain a plasma sample for PK analysis within [ADDRESS_270960] dose of 
study intervention if requested by [CONTACT_1689] (determined on a case -by-case 
basis).  
4. Document approp riately in the eCRF.  
Decisions regarding dose interruptions or modifications will be made by [CONTACT_203790].  
6.8 CONCOMITANT THERAPY   
Any medication or vaccine (including over -the-counter or prescription medici nes, vitamins, 
and/or herbal supplements)  that the participant is receiving at the time of enrollment or receives 
during the study must be recorded along with:  
• Reason for use.  
• Dates of administration including start and end dates.  
• Dosage information includ ing dose and frequency.  
The Medical Monitor should be contact[CONTACT_63193].  
Participants must abstain from taking prescription or nonprescription drugs (including vitamins, 
recreational drugs, and diet ary or herbal supplements) within 7 days (or 14 days if the drug is a 
potential enzyme inducer) or 5 half -lives (whichever is longer) before the start of study 
intervention until completion of the follow -up visit, unless, in the opi[INVESTIGATOR_225319], the medication will not interfere with the study.  
6.8.1  Prohibited medications   
Any medications listed in exclusion criteria ( E 19, E 20, E 21, E 22 and E 23) should not be 
initiated during the study except what specifically mentioned in rescue medicine section 
(Section  6.8.8 ). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 49 6.8.2  Topi[INVESTIGATOR_225320] (Appen dix 10, Section  10.10.1 ) 
are allowed from baseline if they are initiated [ADDRESS_270961] be not ified timely (eg, within 1 working day). The 
allowed cumulative dose of oral corticosteroid is equivalent prednisone <60  mg/day x [ADDRESS_270962] 12 weeks prior to Sc reening visit and not exceed 2.3  mg/kg/day for chloroquine, 400mg/day 
for hydroxychloroquine. No change is allowed during the Screening period. Whenever possible, 
the dose should be stable during entire study period except that the patient develops an AE n ot 
related to CLE or SLE requiring the modification. The modification and AE must be recorded in 
the eCRF.  
6.8.6  Nonsteroidal anti -inflammatory drugs, topi[INVESTIGATOR_12866], acetaminophen and 
other analgesic   
Paracetamol/Acetaminophen, at doses of ≤2 grams/day, is permitted for use any time during the 
study. Other concomitant medication may be considered on a case -by-case basis by [CONTACT_3786], if they do not interfere with the study including any study assessments.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 50 6.8.7  Drug interaction   
6.8.8  Rescue medications   
Topi[INVESTIGATOR_11930] a nd/or topi[INVESTIGATOR_125039]/or one short course of oral 
corticosteroids  of up to 10 days are allowed as rescue medications. If other systemic rescue 
medications such as immunosuppressants (except initiation or increase the dose of chloroquine or 
hydroxychloroquine) are required, the patient should be permanently discontinued from the study 
drug, but they should be encouraged to stay in the study until the end of the study.  
Subjects requiring rescue therapy (addition or increase of any systemic or topi[INVESTIGATOR_12969]) 
beyond baseline will be considered non -responders.  
Rescue medication should not be used for at least [ADDRESS_270963] be recorded.  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 51 7 DISCONTINUATION OF S TUDY INTERVENTION AN D 
PARTICIPANT DISCONTI NUATION/WITHDRAWAL     
7.1 DISCONTINUATION OF S TUDY INTERVENTION   
7.1.1  Perm anent  discontinuation   
In rare instances, it may be necessary for a participant to permanently discontinue (definitive 
discontinuation) study intervention. If study intervention is definitively discontinued, the 
participant will remain in the study to be evaluated . Remaining visits will be performed, details 
are in Section  [IP_ADDRESS] . 
See the SoA for data to be collected at the time of discontinuati on of study intervention and 
follow -up and for any further evaluations that need to be completed.  
The IMP will be permanently discontinued in case of the following events:  
• Clinically significant infections such as:  
- Opportunistic infections  
- Active TB  
- COVID -19 infections (positive -PCR or suspected active COVID -19 infection)  
• New adenopathy of unknown cause  
• New diagnosed malignancies  
• Initiation of systemic rescue medication except one short course of oral corticosteroid 
<10 days and/or chloroquine or hydr oxychloroquine  
• Significant laboratory abnormalities (See Appendix 6 [Section  10.6]): 
- ALT >[ADDRESS_270964] or ALT >[ADDRESS_270965] with concomitant total bilirubin >[ADDRESS_270966] (unless 
patient with documented Gilbert’s syndrome)  
• Hb <8 g/dl of unknown cause  
• Symptomatic overdose  
• Pregnancy in female participant  
• Any AEs, per Investigator’s judgement that discontinuation of study intervention is in best 
interest of th e participant  
Any abnormal laboratory value or ECG parameter will be immediately rechecked for 
confirmation before making a decision of definitive discontinuation of the IMP for the concerned 
participant.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 52 [IP_ADDRESS]  Handling of participants after permanent interventi on discontinuation   
Participants will be followed -up according to the study procedures specified in this protocol up to 
the scheduled date of study completion, or up to recovery o r stabilization of any AE to be 
followed -up as specified in this protocol, whichever comes last.  
If possible, and after the definitive early discontinuation of intervention, the participants will be 
assessed using the procedure normally planned for the las t dosing day with the IMP (end of 
treatment [EOT ] visit) including skin biopsy sample and PK sample, if appropriate. Then, all the 
remaining visits and associated procedures prespecified in the SOA will be performed, except skin 
biopsy, pharmacokinetic samples, and photography at Week 12.  
All cases of permanent intervention discontinuation must be recorded by [CONTACT_13135] e CRF when considered as confirmed.  
7.1.2  Liver chemistry stoppi[INVESTIGATOR_225321] 
a participant meets one of the conditions outlined in the al gorithm ( Section  10.6) or in the 
presence of abnormal liver chemistries not meeting protocol -specified stoppi[INVESTIGATOR_225322].  
7.1.3  QTc stoppi[INVESTIGATOR_225323] a clinically significant finding is identified (including, but not limited to changes from baseline 
in QT interva l after enrollment), the Investigator or qualified designee will determine if the 
participant can continue in the study and if any change in participant management is needed. This 
review of the ECG printed at the time of collection must be documented. Any new clinically 
relevant finding should be reported as an AE or AESI ( Section  8.3.8 ). 
7.1.4  Temporary disc ontinuation   
Temporary intervention discontinuation may be considered by [CONTACT_225376] ( Section  10.6) or disruption of the clinical trial due to a regional or national 
emergency declared by a governmental agency (Appendix 9: Contingency measures  for a regional 
or national emergency that is declared by a governmental agency [ Section  10.9]). For all 
temporary int ervention discontinuations, duration should be recorded by [CONTACT_225377].  
A temporary discontinuation >7 consecutive days will lead to permanent discontinuation.  
7.1.5  Rechallenge   
Reinitiation of intervention with the IMP will be done under close and appropriate clinical/and or 
laboratory monitoring once the Investigator will have considered according to his/her best medical 
judgment that the resp onsibility of the IMP(s) in the occurrence of the concerned event was 
unlikely and if the selection criteria for the study are still met.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 53 For a regional or national emergency declared by a governmental agency that results in travel 
restrictions, confinemen t, or restricted site access, contingency measures are included in  
Appendix  9 (Section  10.9): Contingency Measures for a regional or n ational emergency that is 
declared by a governmental agency.  
[IP_ADDRESS]  Study intervention restart or rechallenge after liver stoppi[INVESTIGATOR_225324] ( Section  7.1.2 ) are 
met by [CONTACT_103070].  
7.2 PARTICIPANT DISCONTINUATION/WITH DRAWAL FROM THE STUD Y  
• A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the  Investigator for safety, behavioral or 
compliance reasons. This is expected to be uncommon.  
• At the time of discontinuing from the study, if possible, an early discontinuation visit 
should be conducted, as shown in the SoA ( Section  1.3). See SoA for data to be collected 
at the time of study discontinuation and follow -up and for any further evaluations that 
need to be completed.  
• If the pa rticipant withdraws consent for disclosure of future information, the Sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.  
• If a participant withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the Investigator must document this in the site study records.  
If participants no longer wish to take the IMP, they will be encouraged to remain in the study.  
The Investigators should discuss with them key visits to attend. The valu e of all their study data 
collected during their continued involvement will be emphasized as important to the public health 
value of the study.  
Participants who withdraw from the study intervention should be explicitly asked about the 
contribution of possi ble AEs to their decision, and any AE information elicited must be 
documented.  
All study withdrawals should be recorded by [CONTACT_21453]’s medical records. In the medical record, at least the  date of the 
withdrawal and the reason should be documented.  
In addition, a participant may withdraw his/her consent to stop participating in the study. 
Withdrawal of consent for intervention should be distinguished from withdrawal of consent for 
follow -up visits and from withdrawal of consent for non -participant contact [CONTACT_6492] -up, 
eg, medical record checks. The site should document any case of withdrawal of consent.  
Participants who have withdrawn from the study cannot be re -randomized (treated) in the stu dy. 
Their inclusion and intervention numbers must not be reused.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270967] be taken if a participant fails to return to the clinic for a required study 
visit:  
• The site must attempt to contact [CONTACT_21455]/or should continue in 
the study.  
• Before a participant is deemed lost to follow up,  the Investigator or designee must make 
every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, 
if necessary, a certified letter to the participant’s last known mailing address or local 
equivalent methods). These contact  [CONTACT_13140]’s 
medical record.  
• Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study.  
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix  1 (Section  10.1). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 55 8 STUDY ASSESSMENTS AN D PROCEDURES   
• Study procedures and their timing are summarized in the SoA ( Section  1.3). Protocol 
waivers or exemptions are not  allowed.  The clinician reported outcome (ClinRO ) 
mentioned in the SoA will be used when copyright is obtained (if applicable).  
• Adherence to the study design requirements, including those speci fied in the SoA, is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The Investigator will maintain a screening log to 
record details of  all participants screened and to confirm eligibility or record reasons for 
screening failure, as applicable.  
• Procedures conducted as part of the participant’s routine clinical management (eg, blood 
count)  and obtained before signing of the ICF may be util ized for screening or baseline 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame defined in the SoA.  
• Patient -reported outcome (PRO) questionnaires should be completed by [CONTACT_225378] e consultation and/or clinical tests, in a quiet place (at home in e -diary and at 
clinic). The questionnaires should be completed by [CONTACT_125452], 
independently from their physician, the study nurse, or any other medical personnel and 
withou t any help from friends or relatives.  
For a regional or national emergency declared by a governmental agency that results in travel 
restrictions, confinement, or restricted site access, contingency measures are included in  
Appendix  9 (Section  10.9): Contingency Measures for a regional or national emergency that is 
declared by a governmental agency.  
8.1 EFFICACY ASSESSME NTS   
Planned time points for all efficacy  assessments are provided in the SoA ( Section  1.3). 
8.1.1  Cutaneous lupus Erythematosus Disease Area and Severity Index (CLASI)   
The CLASI is a clinician rated scale designed to assess the disease activity and damage in CLE in 
adults. It is composed of 56 items covering two dimensions ( 2): the disease activity (CLASI -A) 
and the disease damage (CLASI -D). The domains covered by [CONTACT_225379]:  
• CLASI -A disease activity  
- Erythema  
- Scale/Hypertrophy  
- Recent hair loss/Alopecia (clinically not obviously scarred)  
- Mucous membrane lesions  
• CLASI -D disease damage  
- Dyspi[INVESTIGATOR_225325]-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 56 • Scarring/Atrophy/Pa nniculitis  
• Clinically judged scarring of the scalp (including scarring alopecia)  
It has a current recall period and takes approximately 5 minutes to complete. Each of the 
two domains can be scored individually, with a higher score indicating a more severe skin disease. 
CLASI -A sub -score ranges from 0 to 70, with the following cut -offs: 0 -9 indicating mild disease, 
10-20 indicating moderate disease, and 21 -70 indicating severe disease ( 3). Damage is scored on 
a scale of [ADDRESS_270968] area involved.  
The CLASI is a validated clinical instrument with documented content validity and good 
psychometric properties (inter - and intra - rater reliability; ability to detect changes) ( 2, 18, 19, 20, 
21). A 4 -point or 20% decrease in CLASI -A score represents the minimal clinically important 
change (MCIC) ( 3). 
The CLASI -A50/[ADDRESS_270969] 50%/75% of 
CLASI -A sub -score from baseline.  
Whenever possible, the same patient should be assessed by [CONTACT_225380].  
The CLASI is provided in Appendix 10 ( Section  10.10.2 ). 
Clinicians will complete the CLASI as per SoA ( Section  1.3). 
8.1.2  Physician Global Assessment of disease activity (PhysGA - disease activity) for 
cutaneous lupus erythematosus   
The Physician’s Global Assessment of disease activity (PhysGA - disease activity) is a 5 point -
Lickert scale instrument designed to assess physician -reported disease activity ranging from “Not 
active at all” to “Extremely active”. This instrument has been deve loped internally for this study 
in CLE. Whenever possible, the same patient should be assessed by [CONTACT_225381].  
The PhysGA -disease activity is provided in Appendix 10 ( Section  10.10.3 ). 
Clinicians will complete the PhysGA -disease activity as per SoA ( Section  1.3). 
8.1.3  Physician Global Assessment of Change in cutaneous lupus erythematosus activity 
(PGAC)   
The Physician’s Global Assessment of Change in cutaneous lupus erythematosus (PGAC) is 
a 7-Point Likert scale instrument designed to assess physician -reported evaluation of change in 
patient’s cutaneous lupus erythematosus activity overall in regards of start of treatment. The scale 
is ranged from “Very much improved”  to “Very much worse”.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 57 Whenever possible, the same patient should be assessed by [CONTACT_225380].  
The PGAC is provided in Appendix 10 ( Section  10.10.3 ). 
Clinicians will complete the PGAC as per SoA ( Section  1.3). 
8.1.4  Patient -reported Numerical Rating Scale (NRS)   
The Peak Pruritus NRS (itch -NRS) is a single item PRO tool that patients will use to report the 
intensity of their pruritus (itch) during a daily recall period. Patients will be asked to rate their 
worst itch on a 0 (“No itch”) to 10 (“Worst itch imaginable”) NRS by [CONTACT_134868]: “On a scale of 0 to 10, with 0 being ‘no itch’ and 10 being the ‘worst itch imaginable’, 
how wo uld you rate your itch at the worst moment during the previous 24 hours?”  
The Peak Pruritus NRS has been validated in atopic dermatitis adult and adolescent patients; 
a threshold for clinically relevant, within -person response was found to be 2 -4 points ( 25). 
The Peak Pain NRS (Pain -NRS) is a single item PRO tool that patients will use to report the 
intensity of their CLE -related pain (skin, or al, genital) during a daily recall period. Patients will be 
asked to rate their worst pain on a 0 (“No pain”) to 10 (“Worst pain imaginable”) NRS by 
[CONTACT_16134]: “On a scale of 0 to 10, with 0 being ‘no pain’ and 10 being the 
‘worst pa in imaginable’, how would you rate your pain at the worst moment due to your lupus 
during the previous 24 hours?”.  
The Pain -NRS has been developed specifically for the present study.  
The itch -NRS and Pain -NRS are provided in Appendix 10 ( Section  10.10.4 ). 
Patients will complete the Peak Pruritus NRS and Peak Pain NRS daily, as per the SoA (Section  1.3). 
If acetaminophen or other analgesics or topi[INVESTIGATOR_225326], the participant 
will be requested to rate his/her pain just before the next administration.  
8.1.5  Investigator’s Global Assessmen t for Cutaneous Lupus Erythematosus (IGA -CLE)   
Investigator’s Global Assessment for Cutaneous Lupus Erythematosus (IGA -CLE) is a ClinRO 
that allows for clinicians to assess the ov erall disease activity of CLE using a 5 -point scale: 
0 (clear), 1 (almost clear), 2 (mild), 3 (moderate), and 4 (severe). The Severity of CLE is 
determined by [CONTACT_225382] a combination of 3 plaque characteristics: erythema, scale, 
elevation. Erythema i s the primary characteristic that should influence the rating, with other 
characteristics considered secondarily. Telangiectatic change should not be considered in the 
rating. The assessment does not require the presence of all four characteristics, the se verity is 
averaged over the observed characteristics.  
Whenever possible, the same patient should be assessed by [CONTACT_225380].  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 58 The IGA -CLE is provided in the Appendix 10 ( Section  10.10.8 ) 
Clinicians will complete the IGA -CLE as per SoA ( Section  1.3). 
8.1.[ADDRESS_270970] Profile 14 -item version (OHIP -14)  
The OHIP -14 is a PRO questionnaire that measures people’s perception of dysfunction, 
discomfort and disability attributed to oral conditions in adults ( 26). It is composed of [ADDRESS_270971] 
month. Each of the 14 items has a set of possible answers distributed in a Li kert scale (0 = never, 
1 = hardly ever. 2 = occasionally 3 = fairly often, 4 = very often), which represents the frequency 
that the individual perceives the impact of oral health on seven dimensions: functional limitation 
(2 items), physical pain (2 items) , psychological discomfort (2 items), physical disability 
(2 items), psychological disability (2 items), social disability (2 items) and handicap (2 items) 
(26). The OHIP -14 scores can range from 0 to 56 and are calculated by [CONTACT_225383] 14 items. The domain scores can range from 0 to 8. Higher OHIP -14 scores indicate 
worse oral -health -related quality of life. OHIP -14 shows good reliability, validity and precision.  
The OHIP -14 is provided in Appendix 10 ( Section  10.10.5 ). 
Patients will complete the OHIP -14 as per the SoA ( Section  1.3). 
8.1.7  SKINDEX -29+3   
Skindex -29 is a PRO measure designed to assess the effects of skin disease on patients’ 
health -related quality of life in adults ( 27, 28). It is a generic instrument for skin and connective 
tissue diseases. It contains 29 items, distributed across the following domains: emotions 
(10 items), symptoms (7 items), functioning (12 items); and one item about treatment that is not 
part of the total score. Recall period is “during the past week”. Each item is rated on a 5 -point 
Likert scale (never, rarely, sometimes, often, all the time). Individual items are scored from 
[ADDRESS_270972] been extensively documented in various skin 
diseases, including CLE and SLE patients ( 3, 29, 30, 31). No data is available on the ability of the 
instrument to detect changes in CLE/SLE. Important imp act on health -related quality of life is 
defined as a 9.38 -point and a 7.37 -point improvement in the Emotions and Symptoms subscales of 
Skindex -29, respectively ( 32). 
The Skindex 29+3 (also called SkindexLupus) ( 5). It includes a fourth subscale (3 questions) to 
assess lupus -specific issues, ie, photosensitivity and alopecia. Two items, ‘‘I worry about going 
outside because the sun might flare my disease’’ and ‘‘My skin disease prevents me from doing 
outdoor activities’’ relate to photose nsitivity. The average of these two items was used to generate 
a photosensitivity subscale. Construct validity (item -total correlations; known -group validity) has 
been documented ( 33, 34, 35). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 59 The SKINDEX -29+3 is provided in Appendix 10 ( Section  10.10.6 ). 
Patients will complete the SKINDEX -29+3 as per the SoA ( Section  1.3). 
8.1.8  Patient Global Impression of disease severity (PGIS) and Patient Global Impression 
of Change (PGIC) in cutaneous lupus erythematosus   
The PGIS is a 4 -Point Likert scale instrume nt designed to assess patient’s evaluation of the 
severity their disease over the past week ranging from “None” to “Severe”.  
The PGIC is a 7 -Point Likert scale instrument designed to assess patient’s -reported evaluation of 
change in their disease overall i n regard to start of study medication. The scale is ranging from 
“Very much better” to “Very much worse”.  
The PGIS and PGIC are provided in Appendix 10 ( Section  10.10.7 ). 
Patients will complete the PGIS and PGIC as per the SoA ( Section  1.3). 
8.1.9  28-Joint  assessment   
Twenty - eight -joint assessment will be used to assess CLE related joint inflammation by [CONTACT_225384]. An active joint is de fined as joint with swelling 
within joint not due to deformity and/or joint with tenderness.  
Twenty - eight joints include proximal interphalangeal joints (10 joints), metacarpophalangeal 
joints (10), wrists (2), elbows (2), shoulders (2) and knees (2).  
8.1.10  Safety of Estrogens in Lupus Erythematosus National Assessment - Systemic 
Lupus Erythematosus Disease Activity Index (SELENA -SLEDAI)   
The SELENA -SLEDAI has been developed to measure  the disease activity in patients with SLE 
for use in clinical trials ( 22). It has been developed to determine global improvement and 
perform ed in effective and reliable manners in studies ( 36). 
This is a weighted index in which signs and symptoms, laboratory tests for each of the nine organ 
systems are given a weighted score and summed up if present at the time of the visit or in the 
preceding 10 days. The maximum theoretical score for the SELENA -SLEDAI is 105 (all 
24 descriptors present simultaneously) with 0 indicating inactive d isease. A reduction of ≥4  points 
in the SELENA -SLEDAI score from baseline is considered to be a clinically meaningful 
improvement ( 37). 
Clini cians will complete the SELENA -SLEDAI as per the SoA ( Section  1.3). 
8.1.11  Genital Erosive Lichen Planus (GELP) score   
Genital Erosive Lichen Planus score is a scoring system for clinical assessment of GELP in 
women ( 38). The GELP scoring system is based on a simple grading (0 -3) of area of involvement, 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 60 degree of erythema, number of erosions, number of striae and patient -reported pain induced by 
[CONTACT_225385] a co tton swab. Area of genital involvement, erythema, striae, 
number of erosions and pain are registered and scored 0 -3 (0 is none) for each parameter. Vulval 
and vaginal involvement is assessed separately, resulting in a maximum GELP score of 30.  
Clinicians w ill complete the GELP as per the SoA ( Section  1.3). 
8.1.[ADDRESS_270973] some of those lesions or decide to photography all of th em. If oral lesions present at 
baseline, oral lesion should be selected as well.  
The body site(s) and lesion features assessed by [CONTACT_225386].  
The detailed information will be provided in the photography user guide.  
8.2 SAFETY ASSESSMENTS   
This section presents safety assessments other than AEs which are presented in Section  8.3. 
Planned time points for all safety assessments are provided in the SoA ( Section  1.3). 
8.2.1  Physical examinations   
A targeted physical examination including lung auscultation and assessment of consciousness will 
be performe d at time points according to Section  1.3. Care should be taken to examine and assess 
any abnormalities that may be present, as indica ted by [CONTACT_2299]’s medical history.  
• A full physical examination will include, at a minimum, assessments of the 
Cardiovascular, Respi[INVESTIGATOR_696], Gastrointestinal and Neurological  systems, skin, nasal 
cavities, eyes, and ears. Height (screening only) and w eight will also be measured and 
recorded.  
• A brief physical examination will include, at a minimum, assessments of the skin, lungs, 
cardiovascular system, lymphatic system (include but not limited to cervical, axillary, 
inguinal and clavicular lymph nodes) and abdomen (liver and spleen).  
• Investigators should pay special attention to clinical signs related to previous serious illnesses.  
• Any new finding or worsening of previous finding should be reported as a new adverse event.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 61 8.2.2  Vital signs   
Vital signs, including systolic and diastolic blood pressure, pulse rate, temperature and respi[INVESTIGATOR_11943], will be collected and recorded at the time points according to Section  1.3. 
• Temperature, pulse rate, respi[INVESTIGATOR_697], and blood pressure will be assessed. The site of 
temperature measurement should be r ecorded in the eCRF, and the same site should be 
used throughout the study for the same patient.  
• Blood pressure and pulse measurements will be assessed in semi -supi[INVESTIGATOR_103645] a 
completely automated device. Manual techniques will be used only if an au tomated device 
is not available.  
• Blood pressure and pulse measurements should be preceded by [CONTACT_2669] [ADDRESS_270974] 
for the participant in a quiet setting without distractions (eg, television, cell phones).  
• Vital signs (to be taken before blood collect ion for laboratory tests) will consist of 1 pulse 
and 3 blood pressure measurements ([ADDRESS_270975] 1  minute). The average of the [ADDRESS_270976] 12 -lead ECG will be performed at time points according to Section  1.3. Heart rate will 
be recorded from the ventricular rate and the PR, QRS, and QT (identify QTcF) intervals will be 
recorded in the eCRF. The ECG strips or reports will be retained with the source.  
• Single  12-lead ECG wi ll be obtained as outlined in the SoA (see Section  1.3) using an 
ECG machine that automatically calculates the heart rate and measure s PR, QRS, QT, and 
QTcF intervals. Refer to Section  7 for QTcF  withdrawal criteria and any additional QTcF  
readings that may be necessary.  
8.2.4  Clinical safety laboratory assessments   
See Appendix 2  (Section  10.2) for the list of clinical laboratory tests to be performed and to the 
SoA for the timing and f requency. Additional clinical laboratory tests may be performed based on 
the investigator’s clinical judgement.  
The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the eCRF. The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged 
by [CONTACT_78782]’s condition.  
A laboratory manual will be provided to study sites with additional information for laboratory 
parameters assessed centrally.  
All laboratory tests with values considered clinically significantly abnorma l during participation 
in the study or within [ADDRESS_270977] dose of study intervention should be repeated until the 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 62 values return to normal or baseline or are no longer considered clinically significant by [CONTACT_208550].  
• If such values do not return to normal/baseline within a period of time judged reasonable 
by [CONTACT_737], the etiology should be identified, and the Sponsor notified.  
• All protocol -required laboratory assessments, as defined in Appendix 2 ( Section  10.2), 
must be conducted in accordance with the laboratory manual and the SoA.  
• If laboratory values from non -protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are considered 
clinically significant by [CONTACT_737] (eg, SAE or severe AE or dose modification), then 
the results must be recorded in the eCRF.  
8.2.5  Suicidal ideation and behavior risk monitoring   
Not applicable.  
8.3 ADVERSE EVENTS (AES) , SERIOUS ADVERSE EV ENTS (SAES) AND OTHE R 
SAFETY REPORTING   
The definitions of AEs and SAEs can be found in Appendix 3 ( Section  10.3). The definition of 
AESI is provided in Section  8.3.8 . 
The definitions of unsolicited and solicited adverse events can be found in Appendix 3 
(Section  10.3). 
AE will be reported by [CONTACT_2299] (or, when appropriate, by a caregiver, surrogate, or the 
participant’s legally authorized representative).  
The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of  an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that 
caused the participant to discontinue the study (see Section  7). 
The method of recording, evaluating, and assessing causality of AEs and SAEs and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section  10.3). 
8.3.1  Time period and frequency for collecting AE and SAE information   
All SAEs will be collected from the signing of the informed consent form (ICF)  until the 
follow -up visit  at the time p oints specified in the SoA ( Section  1.3). 
All AE will be collected from the signing of the ICF  at the time points specified in the SoA 
(Section  1.3). 
All SAEs and AESI will be recorded and reported to the Sponsor or designee immediately and 
under no circumstance should this exceed 24 hours, as indicated in Appendix 3 ( Section  10.3). 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 63 The Investigator will submit any updated SAE data to the Sponsor within 24  hours of it being 
available.  
Investigators are not obligated to actively seek AE or SAE a fter conclusion of the study 
participation. However, if the Investigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and he/she considers the event to be reasonably 
related to the study interven tion or study participation, the Investigator must promptly notify the 
Sponsor.  
8.3.2  Method of detecting AEs and SAEs   
The method of recording, evaluating, and assessing causality of A E and SAE and the procedures 
for completing and transmitting SAE reports are provided in Appendix 3 ( Section  10.3). 
Care will be taken  not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrences.  
8.3.3  Follow -up of AEs and SAEs   
After the initial AE/AESI/SAE report, the Investigator is required to proactively follow each 
participant at subsequent visits/contacts. At the pre -specified study end -date, all SAEs,  and AEs of 
special interest (as defined in Section  8.3.8 ), will be followed until resolution, stabilization, the 
event is otherwise explained, or the participant is lost to follow -up (as defined in Section  7.3). 
Further information on follow -up procedures is provided in Appendix 3 ( Section  10.3). 
8.3.4  Regulatory reporting requirements for SAEs   
• Prompt notification by [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of 
a study intervention under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the reg ulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC) , and Investigators.  
• Adverse events that are considered expected will be specified in the reference safety 
information (Investigator’s Brochure) . 
• Investigator safety re ports must be prepared for suspected unexpected serious adverse 
reactions (S[LOCATION_003]Rs) according to local regulatory requirements and Sponsor policy and 
forwarded to Investigators as necessary.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 64 • An Investigator who receives an Investigator safety report describ ing a SAE, S[LOCATION_003]R or 
any other specific safety information (eg, summary or listing of SAEs) from the Sponsor 
will review and then file it along with the Investigator’s Brochure  and will notify the 
IRB/IEC, if appropriate according to local requirements. It  is the responsibility of the 
Sponsor to assess whether an event meets the criteria for a S[LOCATION_003]R, and therefore, is 
expedited to regulatory authorities.  
8.3.5  Pregnancy   
It is the responsibility of the investigator to report to the sponsor (or designee), any pregnancy 
occurring in a female study participant or a female partner of male participant, during the study.  
• Details of all pregnancies in female participants and female partner s of male participants  
will be collected after the sta rt of study intervention and until the outcome of the 
pregnancy. Generally, the follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery date.  
• If a pregnancy is reported, the Inves tigator should inform the Sponsor within 24 hours  of 
learning of the pregnancy and should follow the procedures outlined in Appendix 4 
(Section  10.4). 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs.  
8.3.6  Cardiovascular and death events   
Cardiovascular and death events should be reported to the sponsor and/or health authority per 
reporting rules for AEs or SAEs if seriousness criteria met.  
8.3.7  Disease -related events  and/or disease -related outcomes not qualifying as AEs or 
SAEs   
Not applicable.  
8.3.[ADDRESS_270978]  
An AESI  is an AE (serious or nonserious) of scientific and medical concern specific to the 
Sponsor ’s product or program, for which ongoing moni toring and immediate notification by [CONTACT_13147]. Such events may require further investigation in order to 
characterize and understand them. Adverse events of special interest may be added, modified or 
removed during a stud y by [CONTACT_12548].  
• Pregnancy of a female participant entered in a study as well as pregnancy occurring in 
a female partner of a male participant entered in a study with IMP;  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 65 - Pregnancy occurring in a female participant entered in the clinical trial or  in a female 
partner of a male participant entered in the clinical trial. It will be qualified as an SAE 
only if it fulfills one of the seriousness criteria (see Appendix 3 [ Section  10.3]). 
- In the event of pregnancy in a female participant, IMP should be discontinued.  
- Follow -up of the pregnancy in a female participant or in a female partner of a male 
participant is mandatory until the o utcome has been determined (See Appendix 4 
[Section  10.4]) 
• Symptomatic overdose (serious or nonserious) with IMP.  
- An overdose (accide ntal or intentional) with the IMP is an event suspected by [CONTACT_13148] (not based on systematic pi[INVESTIGATOR_12988]) and defined as at least 50% more than intended daily dose within one day.  
• Increase in alanine tra nsaminase (ALT)  
- ≥[ADDRESS_270979] (for participants with normal baseline) or  
- >[ADDRESS_270980] 2 -fold increase from baseline value (for participants with 
abnormal baseline).  
• Other AESI:  
- Anemia (Hb <8 g/dL).  
• Other project specific AESI(s)  
- QTc ≥500 ms (per QTcF).  
- New Lymphadenopathy.  
8.3.[ADDRESS_270981] complaint form within required timelines.  
Appropriate information (eg, samples, labels or documents like pi[INVESTIGATOR_12989]) related to 
product identification and to the potential deficiencies may need to be gathered. The Investigat or 
will assess whether or not the quality issue has to be reported together with an AE or SAE.  
[IP_ADDRESS]  Medical device deficiencies   
Not applicable.  
8.4 PHARMACOKINETICS   
Samples for SAR443122 PK analyses will be collected at the following timepoints as mentioned 
in (Section  1.3): 
• On Day 1, PK sampling within [ADDRESS_270982] morning dose (around C max); 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 66 • On Day [ADDRESS_270983] morning dose (around Cmax) and within 7 to 10 hours after the 
morning doses;  
• On Day 85, PK sampling just before or within [ADDRESS_270984] morning dose (around C max). 
Procedures for PK sample management and analysis will be described in the laboratory manual.  
A maximum of 2 samples may be collected at additional time points during the study if warranted 
and agreed upon between the Investigator and the Sponsor. The timing of sampling may be altered 
during the course of the stu dy based on newly available data (eg, to obtain data closer to the time 
of peak plasma concentrations) to ensure appropriate monitoring.  
The actual date and time (24 -hour clock time) of each sample, and associated IMP intake will be 
recorded.  
8.4.1  Pharmacokinetics handling procedure   
Instructions for the collection and handling of biological samples will be provided by [CONTACT_13151].  
Genetic analyses will not be performed on these plasma samples. Participant confidentiality will 
be maintained. At visits during which plasma samples for the determination of multiple aspects of 
study intervention will be taken, one sample of sufficient volume can be used.  
Drug concentration information that would unblind the study will not be reported to investigative 
sites or blinded personnel until the study has been unblinded.  
8.4.2  Bioanalytical method   
SAR443122 will be assayed by a validated LC/MS method. The details of the bioanalytical 
method will be specified in the laboratory manual.  
8.4.3  Pharmacokinetic parameters   
SAR4431 22 concentrations at selected time points after IMP intake will be reported using 
descriptive statistics. Additional PK parameters such as C max, tmax, and AUC 0-tau and elimination 
half-life [t 1/2z] at steady state will be estimated using a population PK ap proach. These parameters 
will be presented in a separate, stand -alone report.  
8.[ADDRESS_270985] biopsy will be before the 
randomization (either at screening or at Baseline) and the second at EOT visit. Transcriptomic 
analysis (RNA sequencing) will be performed on skin samples obtained from biopsies, to explore 
changes related to treatment and/or disease progression compared t o baseline and placebo controls 
to evaluate their association with the observed clinical responses to SAR443122.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 67 Participants will be asked whether they will consent to the collection of an optional blood sample 
for the isolation of DNA and RNA. These mate rials will be used for exploratory genomic and 
transcriptomic analysis, respectively.  
Blood samples for DNA or RNA isolation will be collected at the timepoints indicated in SoA 
(Section  1.3) from participants who have consented to participate in the genetic analysis 
component of the study. Participation is optional. Participants who do not wish to participate in 
the genetic research ma y still participate in the study.  
Blood samples for RNA isolation will be collected at the timepoints indicated in SoA from 
participants who have consented to participate in the gene expression analysis component of the 
study. Participation is optional. Pa rticipants who do not wish to participate in the genetic research 
may still participate in the study.  
In the event of DNA or RNA seq extraction failure, a replacement genetic blood sample may be 
requested from the participant. Signed informed consent will be required to obtain a replacement 
sample unless it was included in the original consent.  
See Appendix 5 ( Section  10.5) for information regarding genetic research. Details on processes 
for collection and shipment and destruction of these samples can be found in the laboratory 
manual.  
8.6 BIOMARKERS   
Blood and skin biopsy samples collected from subjects in this study may be used to identify and 
measure biomarkers (including optional collections of blood for DNA and/or RNA as discussed 
in Section  8.5) related to the study drug. These samples will be used for scientific research to 
support this study protocol. The infor mation gained from these samples may be used to design or 
improve methods for analyzing, comparing, or combining study data. Plasma from whole blood 
will be used for exploratory research including the development of PD assays and/or exploration 
of target - and disease -related exploratory biomarkers related to RIP kinase -1 inhibition such as 
cytokines, lipi[INVESTIGATOR_805], metabolites, proteome, cellular markers, immune cell phenotypes, and other 
inflammatory biomarkers. All samples, including any for assay development wi ll be shipped to 
the Sponsor or a designated laboratory.  
Blood samples for biomarkers related to CLE will be collected by [CONTACT_225387] ( Section  1.3). Procedures for collecting, processing and shippi[INVESTIGATOR_225327].  
Samples will be tested for changes related to treatment and/or disease progressio n compared to 
baseline and placebo controls to evaluate their association with the observed clinical responses to 
SAR443122, including:  
• PBMC : Whole blood will be collected for PBMC isolation . RIPK1 phosphorylation at 
Serine -166 (pS166 -RIPK1) will be measur ed in lysates prepared from collected PBMCs 
using a qualified fit -for-purpose assay.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 68 • Cytokines Panel, Chemokines  Panel,  and disease related biomarkers : Blood plasma 
will be used for the tests.  
- The cytokine panel includes validated assays for:  
 
- The chemokine  panel includes validated assays for:  
. 
- The disease related biomarkers are referred to as C3, C4, anti -dsDNA -Ab as well as  
other CLE biomarkers.  
• Skin Biopsy for Immunohistochemistry (IHC) : Skin samples obtained from punch 
biopsies will be used for Immunohistochemistry and histology analysis.  
Samples will remain confidential. These samples, and any additional samples  derived from the 
original samples, may be stored and analyzed for up to 15 years after the study ends and the final 
results are reported (or according to local regulations). The Sponsor and its authorized 
representatives will ensure that samples are destr oyed at the end of the storage period.  
The timing of the PD assessments, including blood collections, to be performed during the study 
may be subject to change based on the ongoing review of the data. Furthermore, additional blood 
samples may be taken from  each subject per treatment period per safety purpose. Any changes to 
the scheduled timepoints of PD assessments will be agreed with the Sponsor.  
8.[ADDRESS_270986] participant response to treatment. Therefore, data an d biological samples will be stored 
and used for future research when consented to by [CONTACT_4317] (see Section  10.1.3 ) unless 
prohib ited by [CONTACT_21475]/IECs (in such case, consent for future use of sample will not be 
included in the local ICF ). 
For participants who consent to the future use of biological samples, the left -over samples may be 
used after the study ends for future research related either to the drug, the mechanism of action, 
and the disease or its associated conditions. Such research may include, but is not limited to, 
performing assessments on DNA, RNA, proteins or metabolites. If future research on genetic 
materia l is performed, this will also be limited to the purpose of addressing research questions 
related to the drug, the mechanism of action, the disease or its associated conditions.  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270987] part. Participant’s coded data 
sets provided to researchers for a specific research project will be available to the researchers for 
a maximum of [ADDRESS_270988] (end of project is defined by 
[CONTACT_211289]).  
In the event future research is conducted for other purposes not listed above, the study participants 
will be informed of those purposes and will be given means to object to those research projects. 
An additional written consent will be obtained from participants if this is the case.  
Data and samples will be used in compliance with the information provided to participants in the 
ICF Part 2 (future research) and any applicable data protection laws.  
All study participant data and samples will be coded such that no participant direct identifiers will be 
linked to them. Coded data and samples may be transferred to a Sponsor site ( or a subcontractor site), 
which may be located outside of the country where the study is conducted. The Sponsor adopts 
safeguards for protecting participant confidentiality and personal data (see  Section  10.1.4 ). 
The samples will be stored for a maximum of 15 years after the end of the study. Any samples 
remaining at the end of retention period will be destroyed. If a participant reques ts destruction of 
his/her samples before the end of the retention period, the Investigator must notify the Sponsor 
(or its contract organization) in writing. In such case, samples will be destroyed and related coded 
data will be anonymized unless otherwise  required by [CONTACT_5751].  
Study participant coded data will be stored for future research for up to 25 years after the end of 
the study. If data are still considered of important scientific value after this period, coded data 
already available will be anonymized unless otherwise required by [CONTACT_5751] (the same will 
apply to the data of a study participant who has requested the destruction of his/her samples).  
Participant’s coded data sets provided to researchers for a specific research project wil l be available 
to the researchers for a maximum of [ADDRESS_270989] (end of project is 
defined by [CONTACT_211289]).  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270990] to the primary endpoint (percent change  from Baseline 
in CLASI -A sub -score at Week 12) by [CONTACT_225388] ( 39). Assumin g a standard deviation of 45% and a reducing effect of 
28% under active treatment, a sample size of 80 evaluable participants results in an overall 
probability for a positive decision of more than 50% and a negative decision probability of 20%.  
Up to 88 pa rticipants are expected to be randomly assigned to the IMP, expecting a total of 
80 evaluable participants with approximately 40 evaluable participants per group.  
9.2 POPULATIONS FOR ANAL YSES   
The following populations are defined ( Table  5): 
Table  5 - Populations for analyses   
Population  Description  
Screened  All participants who sign the ICF.  
Randomized  All screened participants who are randomly assigned to the IMP (by [CONTACT_12067]) regardless 
of whether the intervention was received or  not. 
Efficacy  All randomized participants exposed to the IMP, with available Baseline 
assessment of the CLASI -A who did actually receive at least [ADDRESS_270991] IMP administration measurement. Participants will be 
analyze d according to the intervention they actually received.  
Safety  All randomized participants exposed to the IMP (regardless of the amount of 
treatment administered) are included in the safety population. Participants will be 
analyzed according to the intervention they actually received.  
Pharmacokinetic (PK)  All randomized and treated participants without any important deviation related to 
IMP administration, for whom the PK data are considered interpretable. Participants 
having received only placebo w ill not be part of the PK population.  
CLASI -A: Cutaneous Lupus Erythematosus Disease Area and Severity Index - A, ICF: informed consent form, IMP: investigational medicinal 
product, PK: pharmacokinetic.  
Note: “Screened” means a participant's, or their legally acceptable representative’s, agreement to 
participate in a clinical study following completion of the informed consent process.  
9.3 STATISTICAL ANALYSES   
The statistical a nalysis plan (SAP) will include a more technical and detailed description of the 
statistical analyses described in this section. This section is a summary of the planned statistical 
analyses of the most important endpoints including primary and a subset of  secondary endpoints. 
The SAP will be developed and finalized prior to database lock or any interim analysis.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 71 For a regional or national emergency declared by a governmental agency, contingency measures 
are included in Appendix  9 (Section  10.9): Contingency measures for a regional or national 
emergency that is declared by a governmental agency.  
9.3.1  General considerations   
Descriptive analyses will include summarization of quantitative variables (using n, mean, standard 
deviation, inter quartile range, median, minimum, and maximum) and qualitative data 
(by [CONTACT_225389]).  
The baseline value of efficacy parameters is defined as the Day [ADDRESS_270992] (IMP) if the participant is treated, or the last available 
value up to randomization if the participant is not exposed to IMP.  
9.3.2  Primary endpoint(s)   
The primary analysis will be performed on the Efficacy population through a mixed model with 
repeated measurements (MMRM) will be fitted to estimate the difference in percent change in 
CLASI -A from Baseline at Week 12. The model includes fixed effects for baseline CLASI -A, 
post-baseline visit, geographical region, disease subtype, baseline use of chloroquine or 
hydroxychloroquine, intervention group, visit by [CONTACT_225390], and visit -by-
baseline CLASI -A interaction. Stratificati on factors will be included in the analysis model if 
a sufficient number of participants per stratum is available. Details will be specified in the SAP. 
Repeated measurements for each post -baseline visit are taken within subject ( Table  6). Point 
estimate and two -sided 90% confidence interval for the difference of mean percent change 
between the 2  groups (SAR443122 versus placebo) will be derived from the  linear model 
framework.  
Table  6 - Primary endpoint analysis   
Primary endpoint  Statistical analysis methods  
Percent change in CLASI -A score 
from Baseline to Week  12. The difference to placebo of mean percent change from Baseline in CLASI -A at Week  12 
will be derived using a mixed model with repeated measurements (MMRM) including 
fixed effects for baseline CLASI -A, post -baseline visit, geographical region, d isease 
subtype, baseline use of chloroquine or hydroxychloroquine, intervention group, 
visit-by- intervention group interaction, and visit -by-baseline -CLASI -A interaction. 
Repeated measurements for each post -baseline visit are taken within subject. Point 
estimate with 90% confidence interval for the difference of mean percent change at 
Week  12 between the 2  groups (SAR443122 versus placebo) will be derived.  
CLASI -A: Cutaneous Lupus Erythematosus Disease Area and Severity Index - A. 
Observed mean and mean p ercent change from Baseline in the primary endpoint will be 
summarized descriptively by [CONTACT_225391].  
Details on the handling of participants requiring rescue medication will be detailed in the SAP.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 72 9.3.3  Secondary endpoint(s)   
Analysis of secondary efficacy endpoints will be performed on the Efficacy population.  
The secondary endpoints defined as proporti on of patients with Phys -GA disease activity be ing 
either 0 or 1 at Week 12 and proportion of patients with IGA -CLE of 0 or 1 (clear or almost clear) at 
Week 12 ( Table  7) will be calculated using a  logistic regression model with treatment, geographical 
region, disease subtype, baseline use of chloroquine or hydroxychloroquine, and subtype by 
[CONTACT_225392]. Stratification factors will be included in the analysis 
mode l if a sufficient number of participants per stratum is available. Details will be specified in the 
SAP. A 90%  confidence interval for the difference in proportions will be provided by [CONTACT_3382] -
transformation to the natural scale of the corresponding 90%  confi dence interval for the log -odds ratio.  
Table  7 - Selected secondary endpoints analyses   
Secondary endpoint  Statistical analysis methods  
Proportion of pati ents with 
PhysGA -disease activity at 
Week  12 being either 0 or 1  The difference in proportion of subjects with PhysGA -disease activity in 0 or 1 will be 
estimated based on a logistic regression model with treatment, geographical region, disease 
subtype, ba seline use of chloroquine or hydroxychloroquine, and subtype -by-intervention group 
interaction as fixed effects. A 90% confidence interval for the difference will be provided.  
Proportion of patients with 
IGA-CLE score of 0 or 1 (clear 
or almost clear) at Week 12  The difference in proportion of subjects with IGA -CLE score of 0 or 1 will be estimated 
based on a logistic regression model with treatment, geographical region, disease subtype, 
baseline use of chloroquine or hydroxychloroquine, and subtype by [CONTACT_225393]. A 90% confidence interval for the difference will be provided.  
PhysGA -disease activity: Physicians Global Assessment of disease activity; IGA -CLE: Investigator’s Global Assessment for Cutaneous Lupus 
Erythemat osus.  
The observed proportion of subjects with PhysGA -disease activity in 0 or 1 and with IGA -CLE 
score in 0 or 1 will be summarized descriptively by [CONTACT_225391], respectively.  
Secondary endpoints other than adverse events, PCSAs, laboratory tests, ECG parameters, vital 
signs or pharmacokinetic parameters will be summarized descriptively by [CONTACT_225394], and their change from baseline will be presented where applicable.  
Summaries of adverse events, PCSAs, laboratory tests, ECG parameters, vital signs as well as 
pharmacokinetic parameters are described in Section  9.3.5  below.  
Additional details on further analyses of secondary endpoints will be provided in the SAP.  
9.3.4  Exploratory endpoint(s)   
Details on the analysis of exploratory endpoints will be provided in the SAP.  
9.3.5  Analyses of safety data   
The safety evaluation will be based upon the review of the individua l values (clinically significant 
abnormalities), descriptive statistics (summary tables, figures) and, if needed, on statistical 
analysis (appropriate estimations, confidence intervals). No statistical significance tests will be 
performed on safety data.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 73 Potentially clinically significant abnormality (PCSA) values are defined as abnormal values 
considered medically important by [CONTACT_1034], according to predefined criteria/thresholds based 
on literature reviews and defined by [CONTACT_225395], vital signs, and ECG 
parameters.  
All the safety analyses will be performed using the safety population.  
For all safety data variables, the following observation periods are defined and used for 
classification of AEs, determination of on -treatme nt PCSA values, and the last on -treatment value 
for laboratory and vital sign parameters:  
• The pre -treatment period is defined as the time between informed consent signature [CONTACT_225421].  
• The treatment -emergent (TE)  period is defined as the time from the first IMP 
administration up to the EoS visit (EoS included). It may be split further into the following 
periods:  
- On treatment period, defined as the time from the first IMP administration  up to the 
last administration of the IMP +5 days (last day included).  
- Residual treatment period, defined as the time after end of the on -treatment period to 
the EoS visit (EoS included).  
• The post treatment period is defined as the time starting after the TE period.  
[IP_ADDRESS]  Adverse events   
[IP_ADDRESS].1  Definitions   
Adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities 
(MedDRA; version in use by [CONTACT_225396]). Clinical judgment should 
be used to determine the severity of AEs as described in Section  10.3.3 . 
Adverse events will be analyzed in the following 3 categories:  
• Pre-treatment AEs: AEs that developed, worsened or became serious during the 
pre-treatment period.  
• Treatment emergent AEs: AEs that developed, worsened or became serious during the 
treatment -emergent period.  
• Post-treatment AEs: AEs that developed, worsened or became serious during the 
post-treatment period.  
Similarly, the deaths will be analyzed in the pre -treatment, treatment -emergent  and post -treatment 
period.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 74 Analysis of all adverse events  
Adverse event incidence table will be provided by [CONTACT_56497]: all 
TEAEs, all treatment emergent AESI (defined with a PT or a prespecified groupi[INVESTIGATOR_007]), all treatment 
emergent SAEs and all TEAEs leading to permanent treatment discontinuation.  
The AE summaries will be generated with number (%) of participants experiencing at least one 
event.  
Deaths will also be analyzed if applicable.  
Analysis of AEs, SAEs, AESIs, deaths  and PCSAs are summarized in Table  8 and will be detailed 
in the SAP.  
Table  8 - Safety analyses   
Safety measures  Statistical analysis methods  
Adverse events  
• AEs  
• TEAEs  
• SAEs  
• AEs leading to IMP discontinuation or study 
withdrawal  
• AEs leading to death  
• AESIs  
• PCSAs  Treatment -emergent adverse event incidence tables will be 
presented by [CONTACT_9313], high -level group term, high -level 
term, and preferred term for each intervention group and overall, 
showing the number (n) and percentage (%) of participants 
experiencing a TEAE.  
Multiple occurrenc es of the same event in the same participant will 
be counted only once in the tables. The denominator for 
computation of percentages will be the safety population within 
each intervention group. In addition, TEAEs will be described 
according to maximum int ensity and relation to the IMP.  
Adverse events that occur outside the treatment emergent period 
will be listed separately.  
Proportion of patients with at least 1  TEAE, treatment emergent 
SAE, AESI, TEAE leading to death, and TEAE leading to definitive 
treatment discontinuation will be tabulated by [CONTACT_225397].  
The incidence of PCSAs occurring during the TE period will be 
summarized by [CONTACT_225398].  
AE: adverse event, AESI: adverse event of special interest, IMP: investigational medicinal product, PCSA: potentially clinically significant 
abnormality, SAE: serious adverse event, TEAE: treatment -emergent adverse event.  
[IP_ADDRESS]  Vital signs   
Vital signs (respi[INVESTIGATOR_1487], temperature, pulse rate and blood pressure) will be summarized by 
[CONTACT_225399].  
[IP_ADDRESS]  Clinical safety laboratory   
Laboratory results (hematology or clinical chemistry) will be summarized by [CONTACT_225400] e ach intervention 
group.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 75 [IP_ADDRESS]  Electrocardiogram   
Electrocardiogram parameters will be summarized by [CONTACT_225401].  
9.3.6  Analyses of pharmacokinetic data   
[IP_ADDRESS]  Pharmacokinetic parameters   
SAR443122 concentrations at selected time points will be reported by [CONTACT_225402].  
Further details on the analysis of PK parameters will be described in the SAP.  
[IP_ADDRESS]  Pharmacokinet ic/Pharmacodynamic analysis   
The analysis of PK/PD relationship will be described in the SAP.  
9.4 INTERIM ANALYSES   
An interim analysis is planned for this study. The sponsor will make use of this interim analysis  to 
facilitate internal operational decision on the compound development. The interim analysis will be 
performed when around 75% of the patients  have completed study treatment or discontinued the 
study. The interim analysis will not lead to changes in the conduct of the protocol other than 
stoppi[INVESTIGATOR_225328], indicating a lack of equipoise for continued 
recruitment of patients.  The details including the pre -specified rules for stoppi[INVESTIGATOR_225300].  
The interim analysis will evalua te the mean percent change from baseline in CLASI -A at Week 12 
and other selected secondary efficacy endpoints, as well as the safety endpoints as needed. The 
PK and PD relationship could also be explored.  
The interim analysis will be performed by a separa te statistical team, independent of the study 
team. The PK/PD analysis will be performed by a sponsor internal modeling and simulation team, 
also independent of the study team. Only those necessary for conducting the interim analysis and 
those responsible for internal project planning/overall portfolio planning needs (eg, to aid in the 
planning of future studies) will have the access to the interim analyses results before study 
completion. A list of these individuals will be maintained.  
All sponsor internal  personnel with access to unblinding information will be asked to sign a study 
confidentiality agreement before having access to unblinding information. Study team and 
investigational sites will not have access to interim study results, and continue to be blinded to 
individual randomization codes until study completion and database lock . 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 76 10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  
CONSIDERATIONS   
10.1 APPENDIX 1: REGULATO RY, ETHICAL, A ND STUDY OVERSIGHT 
CONSIDERATIONS   
10.1.1  Regulatory and ethical considerations   
• This study will be conduct ed in accordance with the protocol and with the following:  
- Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and the applicable amendments and Council for International 
Organizations of Medical Science s (CIOMS) International Ethical Guidelines.  
- Applicable ICH Good Clinical Practice (GCP) Guidelines.  
- Applicable laws and regulations (eg, data protection law as General Data Protection 
Regulation - GDPR).  
• The protocol, protocol amendments, ICF, Investigator  Brochure, [IDFU] and other 
relevant documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_42379]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval bef ore implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
• Protocols and any substantial amendments to the protocol will require health authority 
approval prior to initiation  except for changes necessary to eliminate an immediate hazard 
to study participants.  
• The Investigator will be responsible for the following:  
- Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance wi th the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
- Determining whether an incidental finding (as per [COMPANY_011] policy) should be returned to 
a participant and, if it meets the appropriate criteria, to ensure the finding is returned 
(an incidental finding is a previously undiagnosed medical condition that is discovered 
unintentionally and is unrelated to the aims of the study for which the tests are being 
performed). The following should be considered when determining the return of an 
incidental finding:  
- The return of such information to the study participant (and/or his/her designated 
healthcare professional, if so designated by [CONTACT_2299]) is consistent with all 
applicable national, state, or regional laws and regulations in the coun try where 
the study is being conducted, and  
- The finding reveals a substantial risk of a serious health condition or has 
reproductive importance, AND has analytical validity, AND has clinical validity.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270993] in the 
site medical files that she/he does not want to know about such findings.  
- Notifying the IRB/IEC of  SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
- Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014  for clinical studies  (if applicable), European Medical Device Regulation 
2017/745 for clinical device research (if applicable), and all other applicable local 
regulations.  
As applicable, according to Directive 2001/20/EC, the Sponsor will be responsible for obtaining 
approval  from the Competent Authorities of the EU Member States and /or Ethics Committees, as 
appropriate, for any amendments to the clinical trial that are deemed as “substantial” (ie , changes 
which are likely to have a significant impact on the safety or physical  or mental integrity of the 
clinical trial participants or on the scientific value of the trial) prior to their implementation.  
10.1.2  Financial disclosure   
Investigators and sub -Investi gators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests during the course of the study and for 
1 year after completion of the study.  
10.1.3  Informed consent process   
• The Investigato r or his/her representative will explain the nature of the study to the 
participants , and answer all questions regarding the study, including what happens to the 
participant when his/her participation ends (post -trial access strategy for the study).  
• Partic ipants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 
50, local regulations, ICH guidelines, Privacy and Data Protection requirements inclu ding 
those of the Global Data Protection Regulation (GDPR) and of the French law, Health 
Insurance Portability and Accountability Act (HIPAA) requirements, where applicable, 
and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 78 • In case of ICF amendment while the participan ts are still included in the study, they must 
be re -consented to the most current version of the ICF(s). Where participants are not in the 
study anymore, teams in charge of the amendment must define if those participants must 
or not re -consent or be inform ed of the amendment (eg, if the processing of personal data 
is modified, if the Sponsor changes, etc).  
• A copy of the ICF(s) must be provided to the participant . 
Participants who are rescreened are required to sign a new ICF.  
The ICF contains 2 separate sec tions that addresses the use for research of participants’ data 
and/or samples (remaining mandatory ones or new extra samples collected for optional research). 
Optional exploratory research must be detailed in the section “Optional tests/procedures” and 
future research is to be defined in Core Study Informed Consent Form (CSICF) Part 2. Each 
option is subject to an independent consent and must be confirmed by [CONTACT_13158] a checkbox in 
CSICF Part 3. The Investigator or authorized designee will explain to each pa rticipant the 
objectives of the exploratory research and why data and samples are important for future research. 
Participants will be told that they are free to refuse to participate and may withdraw their consent 
at any time and for any reason during the storage period.  
For a regional or national emergency declared by a governmental agency that results in travel 
restrictions, confinement, or restricted site access, contingency measures are included in  
Appendix  9 (Section  10.9): Contingency Measures for a regional or national emergency that is 
declared by a governmental agency.  
10.1.4  Data protection   
All personal data collected and/or processed in relation to this study will be handled in 
compliance with all applicable Privacy & Data Protection laws and regulations, includin g the 
GDPR (General Data Protection Regulation). The study Sponsor is the [COMPANY_011] company 
responsible for ensuring compliance with this matter, when processing data from any individual 
who may be included in the [COMPANY_011] databases, including Investigators, nu rses, experts, service 
providers, Ethics Committee members, etc.  
When archiving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor takes all appropriate measures to safeguard and prevent access to this 
data b y any unauthorized third party.  
Protection of participant data  
Data collected must be adequate, relevant and not excessive, in relation to the purposes for which they 
are collected. Each category of data must be properly justified and in line with the study objective.  
Participant race and ethnicity will be collected in this study because they are expected to modify 
the drug response and because they are required by [CONTACT_17513] (eg, on African American 
population for the FDA). They will not be co llected in the countries where this is prohibited by 
[CONTACT_1295].  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 79 • Participants will be assigned a unique identifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor or its service providers will be identifiable o nly 
by [CONTACT_13160]; participant names or any information which would make the 
participant identifiable will not be transferred to the Sponsor.  
• The participant must be informed that his/her personal study -related data will be used by 
[CONTACT_1034] i n accordance with applicable data protection laws. The level of disclosure 
must also be explained to the participant as described in the informed consent.  
• The participant must be informed that his/her medical records may be examined by 
[CONTACT_208047], by [CONTACT_6667]/IEC members, and by [CONTACT_6668].  
• Participants must be informed that their study -related data will be used for the whole “drug 
development program”, ie, for this trial as well as for the following steps necessary for the 
development of the investigational product, including to support negotiations with payers 
and publication of results.  
Protection of data related to professionals involved in the study  
• Personal data (eg, contact [CONTACT_8972], affiliation(s) details, job title and related professional 
information, role in the study, professional resume, training records) are necessary to 
allow [COMPANY_011] to manage involvement in the study and/or the rela ted contractual or pre -
contractual relationship. They may be communicated to any company of the [COMPANY_011] group 
(“[COMPANY_011]”) or to [COMPANY_011] service providers, where needed.  
• Personal data can be processed for other studies and projects. At any time, objection to 
processing can be made by [CONTACT_13164] (link available at 
[COMPANY_011].com).  
• In case of refusal to the processing of personal data by [CONTACT_13165], it will be 
impossible to involve the professionals in any [COMPANY_011] study. In case the professionals have 
already been involved in a [COMPANY_011] study, they will not be able to object to the processing of 
their personal data as long as they are required to be processed by [CONTACT_5279]. 
The same rule applies in case the profe ssionals are listed on a regulatory agencies 
disqualification list.  
• Personal data can be communicated to the following recipi[INVESTIGATOR_840]:  
- Personnel within [COMPANY_011] or partners or service providers involved in the study.  
- Judicial, administrative and regulatory autho rities, in order to comply with legal or 
regulatory requirements and/or to respond to specific requests or orders in the 
framework of judicial or administrative procedures. Contact [CONTACT_225403].  
• Personal data may be transferred towards entities located outside the Economic European 
Area, in countries where the legislation does not necessarily offer the same level of data 
protection or in countries not recogn ized by [CONTACT_225404]. Those transfers are safeguarded by [CONTACT_13168], notably:  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270994] contractual clauses of the European Commission for tr ansfers towards 
our partners and service providers,  
- [COMPANY_011]’s Binding Corporate Rules for intra -group transfers.  
• Professionals have the possibility to lodge a complaint with [COMPANY_011] leading Supervisory 
Authority, the “Commission Nationale de l’Informatique e t des Libertés” (CNIL) or with 
any competent local regulatory authority.  
• Personal data of professionals will be retained by [CONTACT_13169] (30) years, unless 
further retention is required by [CONTACT_5279].  
• In order to facilitate the maintenance of Investigators personal data, especially if they 
contribute to studies sponsored by [CONTACT_13170], [COMPANY_011] participates 
in the Shared Investigator Platform (SIP) and in the TransCelerate Investigator Registry 
(IR) project ( https://transceleratebiopharmainc.com/initiatives/investigator -registry/). 
Therefore, personal data will be securely shared by [CONTACT_13171]. This sharing allows Investigators to keep 
their da ta up -to-date once for all across pharmaceutical companies participating in the 
project, with the right to object to the transfer of the data to the TransCelerate project.  
• Professionals have the right to request the access to and the rectification of their  personal 
data, as well as their erasure (where applicable) by [CONTACT_225405]: [COMPANY_011] DPO - 54 rue La Boétie - [ZIP_CODE] PARIS - [LOCATION_009] (to contact [CONTACT_13173], visit https://www.sanofi.com/en/our -responsibility/sanofi -global -privacy -
policy/contact).  
10.1.5  Committee structure   
[IP_ADDRESS]  Internal Safety Review Committee   
This study will estab lish an unblinded ISRC which is independent from study team and 
Investigators to conduct the review of safety data (all AEs, including SAE and AESIs) as well as 
selected clinical laboratory parameters, and to make recommendations to the study team regardin g 
the continuation, modification including additional safety measures, a temporary halt or 
termination of the trial. The assessment of available safety data and selected clinical laboratory 
data (as defined in the ISRC charter) will be done periodically. E nrollment may be held during the 
safety review only on the recommendation of the ISRC at their discretion. The ISRC chair may 
call for Ad hoc meetings at any point if the ongoing safety report data warrants this measure in 
their judgement. The structure, m embership and exact responsibilities of the ISRC are detailed in 
the respective charter.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 81 10.1.6  Dissemination of clinical study data   
Study participants  
[COMPANY_011] shares information about clinical trials and results on publicly accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other 
clinical trial disclosure commitments established by [CONTACT_225406]. These 
websites include clinicaltrials.gov , EU clinicaltrialregister (eu.ctr) , and sanofi.com , as well as 
some national registries.  
In addition, results from clinical trials in patients are required to be submitted to peer -reviewe d 
journals following internal company review for accuracy, fair balance and intellectual property. 
For those journals that request sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to submit their  request to vivli.org.  
Individual participant data and supporting clinical documents are available for request at vivli.org. 
While making information available we continue to protect the privacy of participants in our 
clinical trials. Details on data shari ng criteria and process for requesting access can be found at 
this web address: vivli.org . 
Professionals involved in the study or in the drug development program  
[COMPANY_011] may publicly disclose, and communicate to relevant authorities/institutions, the funding, 
including payments and transfers of value, direct or indirect, made to healthcare organizations and 
professionals and/or any direct or indirect advantages and/or any related information or document 
if required by [CONTACT_1289], by [CONTACT_225407] b y a code of conduct such as the “EFPIA Code on 
Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and 
Healthcare Organizations”.  
10.1.7  Data quality assurance   
• All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the Sponsor or designee electronically (eg, laboratory data). The 
Investigator is responsible for verifying that data entries are a ccurate and correct by 
[CONTACT_1189].  
• Guidance on completion of CRFs will be provided in CRF completion instructions.  
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspec tions and provide direct access to source data documents.  
• Monitoring details describing strategy (eg, risk -based initiatives in operations and quality 
such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, respons ibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided in separate study documents.  
• The Sponsor or designee is responsible for the data management of this study  including 
quality checking of the data.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 82 • The Sponsor assumes accountability for actions delegated to other individuals 
(eg, Contract Research Organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be reta ined by [CONTACT_13177] 25 years after the signature [CONTACT_13258] a longer retention period. No 
records may be destroyed during the retention period without the written approval o f the 
Sponsor. No records may be transferred to another location or party without written 
notification to the Sponsor.  
10.1.8  Source documents   
• Source documents provide evidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the Investigator’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the  source documents or the discrepancies must be 
explained. The Investigator may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• Definition of what constitutes source data  can be found in the Monitoring Pla n. 
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• Study monitors will perform ongoing source data verification to confirm that data entered 
into the C RF by [CONTACT_1191], complete, and verifiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.[ADDRESS_270995] of screening  and will be the study start date.  
Study/Site termination  
The Sponsor or designee reserves the right to close the study site  or terminate the study at any 
time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 83 Reasons for study termination by [CONTACT_1034], as well as reasons for the early closure of a study 
site by [CONTACT_125491]:  
• For study termination:  
- Information on the product leads to doubt as to the benefit/risk ratio.  
- Discontinuation of further study interve ntion development.  
• For site termination:  
- Failure of the Investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor’s procedures, or GCP guidelines.  
- Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by [CONTACT_737].  
- Total number of participants included earlier than expected.  
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regula tory authorities, and any contract research organization(s) 
used in the study of the reason for termination or suspension, as specified by [CONTACT_11005]. The Investigator shall promptly inform the participant and should assure 
appropriate participant therapy and/or follow -up. 
10.1.10  Publication policy   
• The results of this study may be published or presented at scientific meetings. If this is 
foreseen, the Investig ator agrees to submit all manuscripts or abstracts to the Sponsor 
before submission. This allows the Sponsor to protect proprietary information and to 
provide comments.  
• The Sponsor will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, the Sponsor will generally support 
publication of multicenter studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator [INVESTIGATOR_225329]. 
• Authorship will be determined by [CONTACT_14346].  
10.2 APPENDIX 2: CLINICAL  LABORATORY TESTS   
• The tests detailed in Table  9 will be performed.  
• For tests to be performed by [CONTACT_2237], local laboratory results are only 
required in the event that the central laboratory results are not available in time for either 
study intervention administration and/or response evaluation. Additionally, if the local 
laboratory results are used to make either a study intervention decision or  response 
evaluation, the results must be entered into the CRF.  
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section  5 of the protocol.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 84 • Additional tests may be performed at any time during the study as determined necessary 
by [CONTACT_9332].  
• Pregnancy testing.  
Table  9 - Protocol -required laboratory tests   
 
Laboratory tests  Parameters  
Hematology   
 Platelet count  
 Red blood cell (RBC) count  
 Hemoglobin  
 Hematocrit  
 RBC indices : 
 MCV  
 MCH  
 %Reticulocytes  
 White blood cell (WBC) count with differential : 
 Neutrophils  
 Lymphocytes  
 Monocytes  
 Eosinophils  
 Basophils  
Clinical chemistry   
 Blood urea nitrogen (BUN)  
 Creatinine  
 Creatinine phosphokinase (CPK)  
 Glucose [fasting]  
 Potassium  
 Sodium  
 Calcium  
 Aspartate aminotransferase (AST)/Serum glutamic -oxaloacetic transaminase (SGOT)  
 Alanine aminotransferase (ALT)/Serum glutamic -pyruvic transaminase (SGPT)  
 Alkaline phosphatasea 
 Total and direct bilirubin  
 Total protein  
Urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones , [bilirubin, urobilinogen, nitrite, leukocyte 
esterase] by [CONTACT_5230]  
• Microscopic examination (including pyuria, hematuria and urinary casts)  
Spot Urine test  • Urine protein test  
• Urine creatinine test  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 85 Laboratory tests  Parameters  
Pregnancy testing  • Serum or highly sensitive urine  human chorionic gonadotropin (hCG) pregnancy 
test (as needed for women of childbearing potential)b 
Other screening tests  • Please refer to Section  1.[ADDRESS_270996]  
• All study -required laboratory tests will be performed by a central laboratory with 
the exception of:  
- TB screening testing  
- COVID -19 screening testing  
- Follicle -stimulating hormone and estradiol (as needed in women of non -
childbearing potential only)  
- Hepatitis B DNA testing as needed  
The results of each test must be entered into the eCRF.  
NOTES:  
a If alkaline phosphatase is elevated, consider fractionating.  
b Local urine testing will be standard for the protocol unless serum testing is required by [CONTACT_18039]/IEC.  
Investigators must document their review of each laboratory safety report.  
Laboratory/analyte results (eg, PK/PD) that could unblind the study will not be reported to 
investigative sites or other blinded personnel until the study has been unblinded.  
10.3 APPENDIX 3: AES AND SAES: DEFINITIONS AN D PROCEDURES FOR REC ORDING, 
EVALUATING, FOLLOW -UP, AND REPORTING   
10.3.1  Definition of AE   
AE definition  
• An AE is any untoward medical occ urrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered related 
to the study intervention.  
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention.  
Definition of unsolicited and solicited AE  
• An unsolicited adverse event is an adverse event that was not solicited using a part icipant 
diary and that is communicated by a participant who has signed the informed consent. 
Unsolicited AEs include serious and non -serious AEs.  
• Potential unsolicited AEs may be medically attended (ie, symptoms or illnesses requiring 
a hospi[INVESTIGATOR_11956], or  emergency room visit, or visit to/by a health care provider). The 
participants  will be instructed to contact [CONTACT_139138](s), as well as any events that, though not medically attended, are of 
participant  concern. Detailed information about reported unsolicited AEs will be collected 
by [CONTACT_14348]’s records.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 86 • Unsolicited AEs that are not medically attended nor perceived as a concern by [CONTACT_225408].  
• Solicited AEs are predefined local and systemic events for which the participant is 
specifically questioned, and which are noted by [CONTACT_225409].  
Events meeting  the AE definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseli ne, considered clinically significant in the medical 
and scientific judgment of the Investigator (ie, not related to progression of underlying 
disease), eg:  
- Symptomatic and/or  
- Requiring either corrective treatment or consultation, and/or  
- Leading to IMP dis continuation or modification of dosing, and/or  
- Fulfilling a seriousness criterion, and/or  
- Defined as an AESI  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New c onditions detected or diagnosed after study intervention administration even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical seq uelae of a suspected overdose of either study 
intervention or a concomitant medication.  
• “Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy assessme nts. 
However, the signs, symptoms, and/or clinical sequelae resulting from lack of efficacy 
will be reported as AE or SAE if they fulfill the definition of an AE or SAE.  
• The signs, symptoms, and/or clinical sequelae resulting from lack of efficacy will be 
reported as AE or SAE if they fulfill the definition of an AE or SAE. Also, “lack of 
efficacy” or “failure of expected pharmacological action” also constitutes an AE or SAE.  
Events NOT meeting the AE definition  
• Any clinically significant abnormal laborator y findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_13142]’s condition.  
• The disease/disorder being studied or expected progression,  signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 87 • Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).  
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
10.3.2  Definit ion of SAE   
An SAE is defined as any adverse event that, at any dose:  
a) Results in death  
b) Is life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe.  
c) Requires inpatient hospi[INVESTIGATOR_186634] n 
In general, hospi[INVESTIGATOR_12994] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_12332]/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the 
AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.  
d) Results in persistent or significant disability/incapacity  
- The term disability means a subs tantial disruption of a person’s ability to conduct 
normal life functions.  
- This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental  trauma (eg, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e) Is a congenital anomaly/birth defect  
f) Other situations:  
- Medical or scientific judgment should be exercised by [CONTACT_225410]. These events should usually be considered serious.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 88 - Note: The following list of medically important events is intended to serve as 
a guideline for determining which condition has to be considered as 
a medically important event. The list is not inten ded to be exhaustive:  
- Intensive treatment in an emergency room or at home for:  
- Allergic bronchospasm  
- Blood dyscrasias (ie, agranulocytosis, aplastic anemia, bone marrow 
aplasia, myelodysplasia, pancytopenia, etc)  
- Convulsions (seizures, epi[INVESTIGATOR_002], epi[INVESTIGATOR_12995], absence, etc).  
- Development of drug dependence or drug abuse  
- ALT >3 × ULN + total bilirubin >2 × ULN or asymptomatic ALT increase 
>10 × ULN  
- Suicide attempt or any event suggestive of suicidality  
- Syncope, loss of consciousness (except if documented as a  consequence of 
blood sampling)  
- Bullous cutaneous eruptions  
10.3.3  Recording and follow -up of AE and/or SAE   
AE and SAE recording  
• When an AE/SAE occurs, it is the responsibility of the I nvestigator to review all  
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator will then record all relevant AE/SAE information.  
• It is not acceptable for the Investigator to send ph otocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor’s representative in lieu of completion of the required form.  
• There may be instances when copi[INVESTIGATOR_88650]’s representative. In this case, all participant identifiers, with the exception of 
the participant number, will be redacted on the copi[INVESTIGATOR_12997]’s representative.  
• The Investigator will attempt to establish a diagnosis of the event based on  signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of intensity  
The Investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to 1 of the following categories:  
• Mild: An event that is easily tolerated by [CONTACT_2299], causing minimal discomfort and 
not interfering with everyday activities.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 89 • Moderate: An event that causes sufficient discomf ort to interfere with normal everyday 
activities.  
• Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. “Severe” is a category used for rating the 
intensity of an event; and both AEs  and SAEs can be assessed as severe.  
An event is defined as “serious” when it meets at least 1 of the predefined outcomes as described 
in the definition of an SAE, NOT when it is rated as severe.  
Assessment of causality  
• The Investigator is obligated to ass ess the relationship between study intervention and 
each occurrence of each AE/SAE.  
• A “reasonable possibility ” of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than that a relationship cann ot be ruled 
out. 
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervent ion 
administration will be considered and investigated.  
• The Investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For each AE/SAE, the Investigator must  document in the med ical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to  the Sponsor and/or health auth ority . 
However, it is very important that the Investigator always make an assessment of 
causality for every event before the initial transmission of the SAE data to the 
Sponsor and/or health authority . 
• The Investigator may change his/her opi[INVESTIGATOR_61501] -up information 
and send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
Follow -up of AEs and SAEs  
• The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_1034]’s 
representative to elucidate the nature and/or causality of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 90 • If a participant dies during participation in the study or during a recognized follow -up 
period, the Investigat or will provide the health authority and the Sponsor with a copy of 
any post -mortem findings including histopathology.  
• New or updated information will be recorded in the originally submitted documents.  
• The Investigator will submit any updated SAE data to t he Sponsor  within 24 hours of 
receipt of the information.  
10.3.4  Reporting of SAEs   
SAE reporting to the Sponsor  via an electronic data collection tool  
• The primary mechanism for reporting an SAE to the Sponsor’s representative will be the 
electronic data collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection 
tool (see next section) to report the event within 24 hours.  
• The sit e will enter the SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken 
off-line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electronic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form (see next section) or to 
the Sponsor’s representative by [CONTACT_756].  
• Contacts for SAE reporting can be found in Investigator study file . 
SAE reporting to the Sponsor via paper data collection tool  
• Facsimile transmission of the SAE paper data collection tool is the pr eferred method to 
transmit this information to the Sponsor’s representative.  
• In rare circumstances and in the absence of facsimile equipment, notification by [CONTACT_13186] a copy of the SAE data collection tool sent by [CONTACT_225411].  
• Initial notification via telephone does not replace the need for the Investigator to complete 
and sign the SAE data collection tool within the designated reporting time frames . 
• Contacts for SAE reporting can be found in Investigator study file . 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 91 10.4 APPENDIX 4: CONTRACE PTIVE AND BARRIER GU IDANCE   
10.4.1  Definitions   
A woman is considered WOCBP (fertile) from the time of menarche until becoming 
postmenopausal (see below) unless permanently sterile (see below).  
• A postmenopausal state is defined as the period of time after a woman has experienced no 
menses for 12 consecutive months without an alter native medical cause.  
• A high follicle -stimulating hormone (FSH) level in the postmenopausal range may be used 
to confirm a postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT).  
• Females on HRT and whose menopa usal status is in doubt will be required to use one of 
the non -estrogen hormonal highly effective contraception methods if they wish to continue 
their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation 
of postmenopausal status  before study enrollment.  
Permanent sterilization methods include:  
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656]  
• Documented bilateral oophorectomy  
• For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, Mullerian agenesis, androgen insensitivity, gonadal dysgenesis), investigator 
discretion should be applied to determining study entry eligibility.  
Note:  Documentation can come from the site personnel’s review of the participant’s medical 
records, medical examination, or medical history interview.  
If fertility is unclear (eg, amenorrhea in adolescents or athletes ) and a menstrual cycle cannot be 
confirmed before first administration  of study intervention, additional evaluation should be 
considered.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 92 10.4.2  Contraception guidance   
• If locally required, acceptable contraceptive methods are limited to those which inhibit 
ovulation as the primary mode of action  
 
CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:  
Highly effective methodsb that have low user dependency Failure rate of <1% per year when used consistently and 
correctly.  
• Implantable progestogen -only hormone contraception associated with inhibition of ovulationc 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS) c 
• Bilateral tubal occlusion  
• Azoospermic partner (vasectomized or due to a medical cause)  
Azoospermia is a highly effective contraceptive method prov ided that the partner is the sole sexual partner of the 
woman of childbearing potential and the absence of sperm has been confirmed. If not, an additional highly effective 
method of contraception should be used.  
Note: documentation of azoospermia for a mal e participant can come from the site personnel’s review of the 
participant’s medical records, medical examination, or medical history interview.  
Highly effective methodsb that are user dependent  Failure rate of <1% per year when used consistently and correctly.  
• Combined (estrogen - and progestogen -containing) hormonal contraception associated with inhibition of ovulationc 
- oral 
- intravaginal  
- transdermal  
- injectable  
• Progestogen -only hormone contraception associated with inhibition of ovulationc 
- oral 
- injectable  
• Sexual abstinence  
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse 
during the entire period of risk associated with the study  intervention. The reliability of sexual abstinence needs to be 
evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant.  
a Contraceptive use by [CONTACT_225412].  
b Failure rate of <1% per year when used consistently and correctly.  Typi[INVESTIGATOR_21361].  
c Male condoms must be us ed in addition to hormonal contraception  
Note: Periodic abstinence (calendar, symptothermal, post -ovulation methods), withdrawal (coitus interruptus), spermicides only, and 
lactational amenorrhea method (LAM) are not acceptable methods of contraception for  this study. Male condom and female condom should 
not be used together (due to risk of failure from friction).  
• For the Unite Kingdom, acceptable forms of effective contraception include:  
- Established use of oral, injectable, or implantable progestogen -only hormonal 
contraception associated with inhibition of ovulation;  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 93 - Placement of an intrauterine device (IUD) or intrauterine hormone -releasing system 
(IUS);  
- Bilateral tubal occlusion;  
- Male sterilization (provided that the partner is the sole sexual partner o f the WOCBP 
study participant and that the sterilized partner has received medical assessment of the 
surgical success).  
• True abstinence: When this is in line with the preferred and usual lifestyle of the subject. 
(Periodic abstinence [eg, calendar, ovulati on, symptothermal, post -ovulation methods] and 
withdrawal are not acceptable methods of contraception).  
COLLECTION OF PREGNANCY INFORMATION:  
Male participants with partners who become pregnant  
• The Investigator will attempt to collect pregnancy information on any male participant’s 
female partner who becomes pregnant while the male participant is in this study. This 
applies only to male participants who receive the IMP.  
• After obtaining the necessary signed informed consent from the pregnant female partner 
directly, the Investigator will record pregnancy information on the appropriate form and 
submit it to the Sponsor within 24 hours  of learning of the partner’s pregnancy. The 
female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to the Sponsor. 
Generally, the follow -up will be no longer than 6 to 8  weeks following the estimated 
delivery date. Any termination of the pregnancy will be reported regardless of fetal status  
(presence or absence of anomalies) or indication for the procedure.  
Female participants who become pregnant  
• The Investigator will collect pregnancy information on any female participant who 
becomes pregnant while participating in this study. The initial i nformation will be 
recorded on the appropriate form and submitted to the Sponsor within 24 hours  of learning 
of a participant's pregnancy.  
• The participant will be followed to determine the outcome of the pregnancy. The 
Investigator will collect follow -up information on the participant and the neonate and the 
information will be forwarded to the Sponsor. Generally, follow -up will not be required 
for longer than 6 to 8 weeks beyond the estimated delivery date. Any termination of 
pregnancy will be reported, re gardless of fetal status (presence or absence of anomalies) or 
indication for the procedure.  
• Any pregnancy complication or elective termination of a pregnancy for medical reasons 
will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at <22 we eks gestational age) or still birth (occurring at 
>22 weeks gestational age) is always considered to be an SAE and will be reported as 
such.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 94 • Any post -study pregnancy related SAE considered reasonably related to the study 
intervention by [CONTACT_225413]  8.3.5 . While the Investigator is not obligated to actively seek this information  in 
former study participants, he or she may learn of an SAE through spontaneous reporting.  
• Any female participant who becomes pregnant while participating in the stud y will 
discontinue study intervention or be withdrawn from the study.  
10.5 APPENDIX 5: GENETICS   
Use/Analysis of DNA/RNA  
• Genetic variation may impact a participant’s response to study intervention, susceptibility 
to, and severity and progression of disease. Variab le response to study intervention may be 
due to genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology; and/or molecular subtype of 
the disease being treated. Therefore, where local regulations and IRB/IEC allow , a blood 
sample will be collected for DNA and RNA analysis from consenting participants. Skin 
biopsy sample will be collected for RNA analysis from study participant.  
• DNA/RNA samples will be used for research relat ed to SAR443122 or CLE and related 
diseases. They may also be used to develop tests/assays including diagnostic tests related 
to SAR443122 and/or RIPK1 kinase class  and CLE . Genetic research may consist of the 
analysis of one or more candidate genes or the  analysis of genetic markers throughout the 
genome or analysis of the entire genome (as appropriate).  
• DNA/RNA samples will be analyzed for changes related to treatment and/or disease 
progression compared to baseline and placebo controls to evaluate their a ssociation with 
the observed clinical responses to SAR443122. Additional analyses may be conducted if it 
is hypothesized that this may help further understand the clinical data . 
• The samples may be analyzed as part of a multi -study assessment of genetic fac tors 
involved in the response to SAR443122  or study interventions of this class to understand 
study disease or related conditions.  
• The results of genetic analyses may be reported in the clinical study report (CSR) or in 
a separate study summary.  
• The Sponso r will store the genetic samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained while research on SAR443122 or study interventions of this 
class or CLE and related diseases  continues but no longer than 15 years or other period as 
per local requirements.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 95 10.6 APPENDIX 6: LIVER AN D OTHER SAFETY: SUGG ESTED ACTIONS AND 
FOLLOW -UP ASSESSMENT S AND STUDY INTERVENTI ON RECHALLENGE 
GUIDELINES   
 
Neutropenia is to be recorded as an AE only if at least 1 of the criteria listed in the general 
guidelines for reporting adverse events in Section 10.3.3  is met.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270997] 1 of the criteria listed in the general 
guidelines for reporting adverse events in Section  10.3.3  is met.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 97  
*If unable to retest in 72 hours, use original lab results to decide on further reporting/monitoring/discontinuation.  
Note:  
“Baseline” refers to ALT sampled at baseline visit; or if baseline value unavailable, to the latest ALT sampled before the ba seline visit. The 
algori thm does not apply to the instances of increase in ALT during s creening.  
See Section  10.3.3  for guidance on safety reporting.  
Normalization is defined as ≤ ULN or baseline value, if baseline value  is > ULN.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270998] 1 of the criteria listed in the 
general guidelines for reporting adverse events in Section  10.3.3  is met.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_270999] 1 of the criteria in the general 
guidelines for reporting adverse events in Section  10.3.3  is met.  
10.7 APPENDIX 7: AES, ADE S, SAES, SADES, [LOCATION_003]D ES AND DEVICE DEFICI ENCIES: 
DEFINITIONS AND PROC EDURES FOR RECORDING , EVALUATING, FOLLOW -UP, 
AND REPORTING IN MED ICAL DEVICE STUDIES   
Not applicable . 
10.8 APPENDIX 8: COUNTRY -SPECIFIC REQUIREMENT S  
For country -specific contrac eptive guidance, see Section  10.4.2 . 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 100 10.9 APPENDIX 9: CONTINGE NCY MEASURES FOR A R EGIONAL OR NATIONAL 
EMERGENCY THAT IS DE CLARED BY A GOV ERNMENTAL AGENCY   
A regional or national emergency declared by a governmental agency (eg, public health emergency, 
natural disaster, pandemic, terrorist attack) may prevent acce ss to the clinical trial site.  
Contingency procedures are suggested for an emergency that prevents access to the study site, to 
ensure the safety of the participants, to consider continuity of the clinical study conduct, protect 
trial integrity, and assist  in maintaining compliance with Good Clinical Practice in Conduct of 
Clinical Trials Guidance. Sponsor agreement must be obtained prior to the implementation of 
these procedures for the duration of the emergency.  
During the emergency, if the site will be unable to adequately follow protocol mandated 
procedures, alternative treatment outside the clinical trial should be proposed, and 
screening/enrollment/randomization/administration of study intervention may be temporarily 
delayed.  
Attempts should be made t o perform all assessments in accordance with the approved protocol to 
the extent possible. In case this is not possible due to a temporary disruption caused by 
[CONTACT_13193], focus should be given to assessments necessary to ensure the safety of participant s 
and those important to preserving the main scientific value of the study.  
Contingencies implemented due to emergency will be documented.  
The participant or their legally authorized representative should be verbally informed prior to 
initiating any change s that are to be implemented for the duration of the emergency (eg, study 
visit delays/treatment extension, use of local labs).  
Study assessments and procedures  
Use of local clinic or laboratory locations may be allowed when central labs analyses cannot be  
performed due to a government declared national emergency.  
If onsite visits are not possible:  
• remote visits (eg, phone call, virtual consultation, etc) or home visits (eg, home nurses, 
home health vendor, etc) may be planned for the collection of possible  safety and/or 
efficacy data (eg, adverse events, blood sampling, patient -reported questionnaires, etc)  
• visit windows may be extended for assessment of safety and/or efficacy data that cannot 
be obtained remotely [eg, vital signs, physical examination, ECG , CLASI -assessment and 
other physician -assessed questionnaires, index lesion photography, biopsy]. Possibility of 
visit extension and duration of such extension must be discussed on a case by [CONTACT_225414]’s s afety and best interests.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 101 If onsite visits are possible and there is a need to reduce the time spent on site to a minimum, 
combined -approach can be considered:  
• during onsite visit, the focus should be on IMP dispensation, collection of safety 
information ( vital signs, physical examination, adverse events), safety blood collection 
(mainly biochemistry and hematology) and efficacy endpoints (eg, CLASI, PhyGA - 
disease activitiy, IGA -CLE if applicable, etc). However, all efforts should be made to 
perform the me asurements of other parameters for efficacy endpoints. These would 
include photography and biopsy.  
• And to complete other assessments that can be obtained in a remote fashion.  
Study intervention  
The following contingencies may be implemented to make clinica l supplies available to the 
participant for the duration of the emergency.  
• The Direct -to-Patient (DTP) supply of IMP from the PI/site/Sponsor via a Sponsor -
approved courier company where allowed by [CONTACT_225415].  
• Delivery by [CONTACT_225416], following clear defined procedures (IMP 
shipment process, safety protection of patients and staff, data protection etc).  
If a participant has to stop IMP due to a regional or national emergency (eg, COVID -19), 
reinitiation of IMP can only occur once the Investigator has determined, according to his/her best 
judgement, that the contribution of the IMP(s) to the occurrence of the epi[INVESTIGATOR_13000] 
(eg, COVID -19) was unlikely and the selection criteria for the study ar e still met. Reinitiation of 
the study intervention will be done under close and appropriate clinical/and or laboratory 
monitoring.  
Statistical analyses  
The impact of the regional or national emergency declared by a governmental agency on study 
conduct wil l be summarized (eg, study discontinuation or discontinuation/delay/omission of the 
intervention due to the emergency). Any additional analyses and methods required to evaluate the 
impact on efficacy (eg, missing data due to the emergency) and safety will be detailed in the SAP.  
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 102 10.10  APPENDIX 10: ADDITIO NAL APPENDICES   
10.10.[ADDRESS_271000] is indicative and not exhaustive.   
Topi[INVESTIGATOR_225330](s)  Strength  
Super High potency (For Rescue only)    
Betamethasone dipropi[INVESTIGATOR_16847], augmented  Ointment  0.05%  
Clobetasol propi[INVESTIGATOR_225331], Foam, Cream, Ointment  0.05%  
Diflorasone diacetate  Ointment  0.05%  
Halobetasol propi[INVESTIGATOR_225332], Ointment  0.05%  
High (For Rescue Only)    
Amcinonide  Lotion, Cream, Ointment  0.1%  
Betamethasone dipropi[INVESTIGATOR_225333], Cream, Ointment  
Cream, Ointment  
Cream, Ointment, Solution, Lotion, Gel  0.05%  
0.025%  
0.064%  
Betamethasone butyrate propi[INVESTIGATOR_225334], Cream, Ointment  0.05%  
Betamethoasone valerate  Ointment, Foam  
Cream, Ointment  0.05%  
0.12%  
Deprodone propi[INVESTIGATOR_225332], Ointment  0.3%  
Desoximetasone  Cream, Ointment  0.25%  
Dexamethasone propi[INVESTIGATOR_225334], Cream, Ointment  0.1%  
Dexamethasone valerate  Cream, Ointment  0.12%  
Diflorasone diacetate  Cream, Ointment  0.05%  
Diflorcortolone valerate  Solution, Cream, Ointment  0.01%  
Difluprednate  Lotion, Cream, Ointment  0.05%  
Fluocinonide  Solution, Gel, Cream, Ointment  0.05%  
Halcinonide  Solution, Cream, Ointment  0.1%  
Mometasone furoate  Ointment  0.1%  
Medium Potency    
Betamethasone dipropi[INVESTIGATOR_225334]  0.02%  
Betamethasone valerate  Foam, Lotion, Cream  
Lotion, Cream  0.1%  
0.12%  
Clobetasone butyrate  Lotion, Cream, Ointment  0.05%  
Desoximetasone  Cream  0.05%  
Fludroxycortide  Cream, Tape  0.05%, 4 μg/m2 
Flumethasone pi[INVESTIGATOR_225335], Cream, Ointment  0.02%  
Fluocinolone acetonide  Solution, Cream, Ointment  0.025%  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 103 Topi[INVESTIGATOR_225330](s)  Strength  
Hydrocortisone butyrate  Lotion, Cream, Ointment  0.1%  
Hydrocortisone valerate  Cream, Ointment  0.2%  
Mometasone furoate  Lotion, Cream  0.1%  
Prednicarbate  Cream  0.1%  
Prednisolone  Cream, Ointment  0.5%  
Prednisolone acetate  Ointment  0.25%  
Prednisolone valerate acetate  Lotion, Cream, Ointment  0.3%  
Triamcinolone acetonide  Lotion, Cream, Ointment  0.1%  
Low Potency    
Alclometasone dipropi[INVESTIGATOR_225332], Ointment  
Ointment  0.05%  
0.1%  
Desonide  Foam, Gel, Cream, Ointment  0.05%  
Dexamethasone sodium phosphate  Lotion, Cream, Ointment  
Cream, Ointment  0.1%  
0.05%  
Fluocinolone acetonide  Solution, Cream  
Spray  0.01%  
0.007%  
Hydrocortisone acetate  Lotion, Cream, Ointment  ≤1%  
Methylprednisolone  Ointment  0.1%  
 
VV-CLIN-0622028 2.0
A m e n d e d Cli ni c al Tri al Pr ot o c ol 0 2  
S A R 4 4 3 1 2 2 -A C T 1 6 4 0 4  2 2 -N o v -2 0 2 2  
V er si o n n u m b er: [ADDRESS_271001] e of C ut a n e o u s L u p u s Er yt h e m at o s u s Di s e a s e Ar e a a n d S e v erit y I n d e x 
( C L A SI)   
 
V V- C LI N- 0 6 2 2 0 2 8 2. 0 
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 105 10.10.3  Sample of P hysician  Globa l Assessment of disease activity (PhysGA - disease 
activity) and Physician  Globa l Assessment of changes in c utaneous lupus 
erythematosus  activity (PGA C)  
 
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 106 10.10.4  Sample of Patient -Reported Peak Pruritus Numerical Rating Scale (itch -NRS) and 
Peak Pain Numerical Rating Scale (Pain -NRS)   
 
 
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: [ADDRESS_271002] Profile (OHIP -14)  
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 108  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 109  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 110  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 111 10.10.6  Sample of SKINDEX -29+3   
 
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 112  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 113  
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 114 10.10.7  Sample of Patient Global Impression of Change (PGIC) and Severity (PGIS) in 
cutaneous lupus erythematosus   
 
VV-CLIN-0622028 2.0

Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 115 10.10.8  Sample of Investigator’s Global Assessment for Cutaneous Lupus 
Erythematosus Activity (IGA -CLE)   
Instructions:  
Severity is determined by a combination of 3 plaque characteristics (erythema, scale, elevation) 
based on descriptions of each characteristic. Scalp involvement includes an assessment of peri -
follicular keratosis as noted.  Scarring alopecia / areas of permanent scarring on the scalp are NOT 
counted.  
Erythema is the PRIMARY characteristic  that should influence the rating, with plaque 
elevation, scaling and other secondary characteristics considered secondarily.  
Telangiectatic change should NOT be considered.  
Assessment does NOT require all four charac teristics to be present.  
Severity of the morphologic features are AVERAGED over the burden of lesions.  
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 116 Cutaneous Lupus Activity Investigator’s Global Assessment (IGA -CLE)   
Score  Description  
0 – Clear   Erythema  – none   
Scale  – none   
Edema/infiltration  – none   
Follicular involvement  – follicular plugging/follicular hyperkeratosis – absent    
Secondary change  – no vesicles, erosion, crusting   
1 – Almost clear    Erythema  – faint  
Scale  – minimal    
Edema/infiltration  – minimal (barely palpable)   
Follicular involvement  – follicular plugging/follicular hyperkeratosis - minimal  and diffuse   
Secondary change  – no vesicles, erosion, crusting    
2 – Mild  Erythema  – pi[INVESTIGATOR_8745]/mild   
Scale  – thin, patchy   
Edema/infiltration  – mild, palpable, barely visible   
Follicular involvement  – follicular plugging/follicular hyperkeratosis  (recent) in one quadrant of scalp   
Secondary change  – mild superfi cial erosion, crusting present; no vesicles    
3 – Moderate   Erythema  – red erythema   
Scale  – thick, patchy   
Edema/infiltration  – moderately raised, palpable, visible    
Follicular involvement  – follicular plugging/follicular hyperkeratosis  in more than one  quadrant of scalp   
Secondary change  – moderate, superficial erosion, crusting: no vesicles   
4 – Severe   Erythema  – violaceous/bright red erythema   
Scale  – thick, confluent   
Edema/infiltration  – thick, raised, easily palpable, easily visible   
Follicular i nvolvement  – follicular plugging/follicular hyperkeratosis  in more than two quadrants of scalp   
Secondary change  – marked erosion, crusting and/or vesicular change present   
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 117 10.11  APPENDIX 11: ABBREVI ATIONS   
 
AE: adverse events  
AESI:  adverse event of special interest  
ALT : alanine transaminase  
ANA:  antinuclear antibody  
BID: twice a day  
CCLE : chronic cutaneous lupus erythematosus  
CLASI : Cutaneous Erythematosus Disease Area and Severity Index  
CLASI -A: Cutaneous Erythematosus Disease Area and Severity Index - Activity  
CLASI -D: Cutaneous Erythematosus Disease Area and Severity Index -skin damange  
CLE : cutaneous lupus erythematosus  
ClinRO:  clinician reported outcome  
CNS : central nervous syst em 
DAMP:  danger -associated molecular pattern  
DLE : discoid lupus erythematosus  
ECG:  electrocardiogram  
EOS : end of study  
EOT : End of Treatment  
EOT : end of treatment  
FIH: first-in-human  
GELP:  Genital Erosive Lichen Planus  
ID: interface dermatitis  
IGA-CLE : Investigator’s Global Assessment of CLE  
IMP: Investigational medicinal product  
INF: interferon  
ISRC:  internal safety review committee  
itch-NRS : Peak Pruritus Numerical Rating Scale  
LP: lichen planus  
MAD : multiple ascending dose  
NOAEL:  no observed adverse effect level  
NRS:  numerical rating scale  
OHIP -14: Oral Health Impact Profile  
pain-NRS :  Peak Pain Numerical Rating Scale  
PBMC:  peripheral blood mononuclear cell  
PCSA :  potentially clinically significant abnormality  
PD: pharmacodynamics  
PGAC : physician’s g lobal assessment of change in disease activity  
PGIC : patient's global impression of change  
PGIS : patient's global impression of disease severity  
PhysGA -disease activity : physician’s global assessment of disease activity  
PK: pharmacokinetics  
pMLKL:  phosphor ylated mixed lineage kinase domain -like protein  
PRO:  patient reported outcomes  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 118 QoL:  quality of life  
RIPK1 : Receptor -Interacting serine -threonine Protein Kinase 1  
SAE:  serious adverse event  
SCLE : subacute  cutaneous lupus erythematosus  
SELENA -SLEDAI:  Safety of Estrogens in Lupus Erythematosus National 
Assessment -SLE Disease Activity Index  
SGC:  systemic glucocorticoid  
SLE: systemic lupus erythematosus  
TB: tuberculosis  
TE: treatment -emergent  
TEAE:  treatment -emergent adverse event  
TLR: toll-like receptor  
TNF: tumor necrosis factor  
ULN : upper limit of normal  
UV: ultraviolet  
WOCBP:  woman of childbearing potential  
 
10.12  APPENDIX 12: PROTOCO L AMENDMENT HISTORY   
The Protocol amendment summary of changes table for the current amended protocol 0 2 is 
located directly before Table of Contents.  
10.12.1  Amended protocol 01 (10 DEC 2021)   
This amended clinical trial protocol 01 (amendment 01) is considered to be not substantial based 
on the criteria set forth in Article 10(a) of Directive 2001/20/EC of the European Parliament and 
the Council of the European Union. Because it does not significantly impact the safety or 
physical /mental integrity of participants, nor the scientific value of the study.  
Overall Rationale for the Amendment  
The main purpose of this amendment is to remove the 50% randomization cap for the discoid 
cutaneous lupus erythematosus (DLE) subtype.  
Cutaneous Lupus erythematosus (CLE) is a heterogeneous skin disease with a wide spectrum of 
presenting cutaneous manifestations that have been subdivided into several subtypes. The present 
study is targeting the subacute cutaneous lupus erythematosus (SCLE) and disc oid cutaneous 
lupus erythematosus (DLE) subtypes. While the pathophysiology of CLE is not fully understood, 
some publications suggest that the treatment response might be subtype dependent ( 40). DLE is 
known to be the most common subtype ( 9). To optimize the differential assessments of both 
subtypes, the original protocol included a cap at 50% for the DLE subtype. The sponsor now 
decided to remove the cap for the DLE subtype patients for a study population being more 
reflective of the natural distribution of the CLE population and to allow completion of the study 
within a reasonable time.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 119 It is mentioned in the section 8 that “The clinician reported outcome (ClinRO) mentioned in the 
SoA will be used when copyright is obtained (if applicable) ”. Modified Oral Mucositis Index 
(MOMI) will not be used in the study as its full copyright has not been obtained. To improve the 
readability, the sponsor takes this opportunity to remove the text related to MOMI throughout the 
document. Other corrections of discrepancies, minor editorial errors iden tified during initial 
protocol submission and wording clarity have been made as well.  
Protocol amendment summary of changes table  
Section # and Name  [CONTACT_225422](s) i s 
available  
Section 1.1 Synopsis, Section 
4.1 Overall Design, Section 
6.3 Measures to minimize 
bias: randomization and 
blinding  Context related to “a cap of 50% for patients with 
histologically proven DLE will be implemented” 
was removed.  To be more reflective of the natural 
distribution of the CLE population and to 
allow completion of the study within a 
reasonable time.  
Section 1.1 Synopsis, Section 
3 Objectives and Endpoints  
Section 1.3 Schedule of 
Activities (SoA), Section 3.1 
Appropriateness of 
Measurements, Section 8.1.6 
Modified Oral Mucositis Index 
(MOMI), Section 10.9 
Appendix 9: Contingency 
measures for a regional or 
national emergency that is 
declared by a governmental 
agency  Secondary Endpoint: “Change from baseline to 
Week 12 in Modified O ral Mucositis Index 
(MOMI) at Week 12 for patients with oral lesions 
at baseline” is deleted.  
Context related to MOMI was deleted.  To improve the readability as the MOMI 
will not be used in the study because 
copyright wasn’t obtained (as per initial 
plan h ighlighted in Section 8: The 
clinician reported outcome (ClinRO) 
mentioned in the SoA will be used when 
copyright is obtained (if applicable) ).  
Section 2.3.1 Risk 
assessment : table 1  Reorganized table 1  To improve the clarity without content 
change  
Section 6.3 Measures to 
minimize bias: randomization 
and blinding  Replaced “the Investigator should make every 
effort to contact [CONTACT_1034]” by “ he/she may, at 
his/her discretion, contact [CONTACT_225417]”  To improve the appropriateness of  
language related to the unblinding 
process as per a health authority’s 
comment  
Section [IP_ADDRESS] Handling of 
participants after permanent 
intervention discontinuation  Modified “skin biopsy and pharmacokinetics 
sample” to “skin biopsy, pharmacokinetic 
sampl es, and photography at Week 12”.  
Foot note “u” was newly inserted in Section 1.3.  To improve the clarity  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 120 Section # and Name  [CONTACT_9353] 8.1.5 Investigator’s 
Global Assessment for 
Cutaneous Lupus 
Erythematosus (IGA -CLE), 
Section 10.10.8 Sample of 
Investigator’s Global 
Assessment  for Cutaneous 
Lupus Erythematosus 
(IGA-CLE)  Added more detailed information on IGA -CLE 
assessment and provided an example in 
appendix.  To provide a more detailed description of 
IGA-CLE assessment in order to improve 
the clarity  
Section 8.2.[ADDRESS_271003]  Clarified “ QTcB or QTcF ” to “QTcF ”. 
 
Added reference of calculation formula (per 
QTcF)  to “QTc ≥500  ms”. To provide more precision  
Section 8.6 Biomarkers  “Immunohistochemistry analysis” was replaced 
by “Immunohistochemistry and histology 
analysis”.  To provide more precision  
Section 9 Statistical 
Considerations  Aligned the names of the analysis populations 
with current Sponsor’s standard.  
Removed a duplicated content in Section [IP_ADDRESS] 
(The same cont ent is provided in Table 8)  
Added more detail description throughout the 
section  To improve precision and clarity  
All sections throughout  Minor editorial and typographical error 
corrections.  To improve readability and overall quality 
of the document  
 
 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 121 11 REFERENCES   
1. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI 
(Cutaneous Lupus Er ythematosus Disease Area and Severity Index): an outcome instrument 
for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889 -94. 
2. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI 
(Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument 
for cutaneous lupus erythematosus. J Invest Dermatol. 2005;125(5):889 -94. 
3. Klein R, Moghadam -Kia S, LoMonico J, Okawa J, Coley C, Taylor L, et al. Development of 
the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous 
lupus erythematosus. Arch Dermatol. 2011;147(2):203 -8. 
4. Albrecht J, Werth VP. Clinical outcome measures for cutaneous lupus erythematosus. Lupus. 
2010;19(9):[ADDRESS_271004] K, Werth VP. 461  Assessing the content validity 
of the sf -36, the skindex -29+3 patient reported outcomes (pro) instruments, and pain, fatigue 
in patients with cutaneous lupus erythematosus (cle). Lupus Scienece & Medicine. 
2017;4(suppl 1):abstr 4 61. 
6. Wenzel J, Tüting T. Identification of type I interferon -associated inflammation in the 
pathogenesis of cutaneous lupus erythematosus opens up options for novel therapeutic 
approaches. E xp Dermatol. 2007;16(5):[ADDRESS_271005] Dermatol. 2018;138(8):[ADDRESS_271006] keratinocytes v ia JAK2/STAT1 in lichen planus. Sci Transl Med. 
2019;11(511):eaav7561.  
9. Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the 
association with systemic lupus ery thematosus: a population -based cohort of 1088 patients in 
Sweden. Br J Dermatol. 2011;164(6):1335 -41. 
10. Biazar C, Sigges J, Patsinakidis N, Ruland V, Amler S, Bonsmann G, et al. Cutaneous lu pus 
erythematosus: first multicenter database analysis of 1002 patients from the European Society 
of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev. 2013;12(3):444 -54. 
11. Jarukitsopa S , Hoganson DD, Crowson CS, Sokumbi O, Davis MD, Michet Jr C, et al. 
Epi[INVESTIGATOR_225336] a 
predominantly white population in the [LOCATION_002]. Arthritis Care Res (Hoboken). 
2015;67(6):817 -28. 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 122 12. Patel P, Werth V. Cutaneous lupus erythematosus: a review. Dermatol Clin. 2002;20(3):373 -
85. 
13. Wenzel J. Cutaneous lupus ery thematosus: new insights into pathogenesis and therapeutic 
strategies. Nat Rev Rheumatol. 2019;15(9):519 -32. 
14. Kuhn A, Aberer E, Bata -Csörgő Z, Caproni M, Dreher A, [LOCATION_009]s C, et al. S2k gui deline for 
treatment of cutaneous lupus erythematosus - guided by [CONTACT_225418] 
(EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). 
J Eur Acad Dermatol Venereol. 2017;31(3):389 -404. 
15. Chang J, Werth VP. Therapeutic options for cutaneous lupus erythematosus: recent advances 
and future prospects. Expert Rev Clin Immunol. 2016;12(10):1109 -21. 
16. Drake LA, Dinehart SM, Farmer ER, Goltz RW, Graham GF, Hordinsky MK, et al. 
Guidelines of care for cutaneous lupus erythematosus. American Academy of Dermatology. J 
Am Acad Dermatol. 1996;34(5 Pt 1):830 -6. 
17. Alves P, Bashir MM, Wysocka M, Zeidi M, Feng R and Werth VP. Quinacrine suppresses 
tumor necrosis factor -α and IFN -α in dermatomyositis and cutaneous lupus erythematosus. J 
Investig Dermatol Symp Proc. 2017;18(2):S57 -63. 
18. Krathen MS, Dunham J, Gaines E, Junkins -Hopkins J, Kim E, Kolasinski SL, et al. The 
Cutaneous Lupus Erythematosus Disease Activity and Severity Index: expansion for 
rheumatology and dermatol ogy. Arthritis Rheum. 2008;59(3):338 -44. 
19. Jolly M, Kazmi N, Mikolaitis RA, Block JA. Validation of the cutaneous lupus disease area 
and severity Index (CLASI)for Lupus. J Invest Med. 2011;5 9(4):723 -4. 
20. Bonilla -Martinez ZL, Albrecht J, Troxel AB, Taylor L, Okawa J, Dulay S, et al. The 
cutaneous lupus erythematosus disease area and severity index: a responsive instrument to 
measure activity and damage in patients with cutaneous lupus erythematosus. Arch Dermatol. 
2008;144(2):173 -80. 
21. Namas R, Powell C, Kahlenberg JM. Anti -Ro Positivity Is a Predictor of Responsiv eness to 
Topi[INVESTIGATOR_225337]. Arthritis Rheumatol. 2016; 68 (suppl 10):1003 -4. 
22. Petri M, Kim MY, Kalunian KC, Gr ossman J, Hahn BH, Sammaritano LR, et al. Combined 
oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 
2005;353:2550 -8. 
23. Weisel K, Berger S, Papp K, Maari C, Kruege r JG, Scott N, et al. Response to inhibition of 
receptor -interacting protein kinase 1 (RIPK1) in active plaque psoriasis: A randomized 
placebo -controlled study. Clin Pharmacol Ther. 2020;108(4):808 -16. 
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 123 24. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and 
validation of the Systemic Lupus International Collaborating Clinics classification criteria for 
systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677 -86. 
25. Yosipovitch G, Reaney M, Mastey V, Eckert L, Abbé A, Nelson L, et al. Peak Pruritus 
Numerical Rating Scale: psychometric validation and responder definition for assessing itch in 
mode rate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):[ADDRESS_271007] profile. Community 
Dent Oral Epi[INVESTIGATOR_5541]. 1997;25(4) :284-90. 
27. Chren M. M, Lasek R. J, Quinn L. M, Mostow EN, Zyzanski SJ. Skindex, a quality -of-life 
measure for patients with skin disease: reliability, validity, and responsiveness. J Invest 
Dermatol. 1996;107(5):707 -13. 
28. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative 
capability of a refined version of Skindex, a quality -of-life instrument for patients with skin 
diseases. Arch Dermatol. 1997;133(11):[ADDRESS_271008] of skin damage due to cutaneous 
lupus on quality of life. Br J Der matol. 2014;170(2):315 -21. 
30. Ishiguro M, Hashizume H, Ikeda T, Yamamoto Y, Furukawa F. Evaluation of the quality of 
life of lupus erythematosus patients with cutaneous lesions in Japan. Lupu s. 2014;23(1):93 -
101. 
31. Janowski K, Steuden S, Bereza B. The Polish version of Skindex -29: psychometric properties 
of an instrument to measure quality of life in dermatology. Postepy Dermato l Alergol. 
2014;31(1):12 -20. 
32. Chakka S, Krain R, Ahmed S, Feng R, Werth VP. Evaluating meaningful change in disease 
activity as a clinical efficacy measure for clinical trials in cutaneous lupus erythematosus. 
Journal of Investigative Dermatology.2019;139([ADDRESS_271009]):S101.  
33. Klein R, Moghadam -Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in 
cutaneous lupus  erythematosus. J Am Acad Dermatol. 2011;64(5):849 -58. 
34. Foering K, Goreshi R, Klein R, Okawa J, Rose M, Cucchiara A, Werth VP. Prevalence of self -
report photosensitivity in cutaneous lupus erythematosus. J Am Acad Dermatol. 
2012;66(2):[ADDRESS_271010] of smoking 
in cutaneous lupus erythematosus [published cor rection appears in Arch Dermatol. 
2012;148(12):1369]. Arch Dermatol. 2012;148(3):[ADDRESS_271011] oxychloroquine in older patients with systemic lupus erythematosus: a 
multicenter retrospective study. Arthritis Res Ther 2020;22(1):191.  
VV-CLIN-0622028 2.0
Amended Clinical Trial Protocol 02  
SAR443122 -ACT16404  22-Nov-2022  
Version number: 1 
 
Property of the [COMPANY_011] group - strictly confidential  Page 124 37. Gladman DD, Urowitz MB, Kagal A, Hallett D. Accura tely describing changes in disease 
activity in systemic lupus erythematosus. J Rheumatol. 2000;27:377 -9. 
38. Helgesen A, Warloe T, Pripp A, Kirschner R, Peng Q, Tanbo T, et al. Vulvovaginal 
photodynamic therapy vs. topi[INVESTIGATOR_225338]: a 
randomized controlled trial. Br J Dermatol, 2015;173:1156 -62. 
39. Quan H, Chen X, Lan Y, Luo X, Kubiak R, Bon net N, et al. Applications of bayesian analysis 
to proof -of-concept trial planning and decision making. Pharm Stat. 2020;19(4):[ADDRESS_271012] measurement of clinical improvement in patients with 
cutaneous lupus erythematosus. Lupus Sci Med. 2020;7(1):e000364.  
 
 
VV-CLIN-0622028 2.0
Signature [CONTACT_11032]-CLIN-0622028 v2.0
act16404-16-1-1-amended-protocol02
Approve & eSign
Approve & eSign
VV-CLIN-0622028 2.0
